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 Depression is a common problem in heart failure (HF) patients and leads to worsened 
health outcomes. A review of studies treating depression in HF patient’s revealed different 
patterns of depressive symptoms. Using the Biopsychosocial Holistic Model of Cardiovascular 
Health as the guiding framework, this study aimed to determine: (a) the prevalence of depressive 
symptoms; (b) determine if there are patterns of depressive symptoms; (c) investigate if the 
patterns differ by gender or pharmacologic treatment; and (d) determine the cardiovascular 
health markers and the biological, psychological, and social factors associated with depressive 
symptoms in HF patients.  
 This descriptive, correlational study was a secondary analysis using data from The Self-
Management and Care of Heart Failure Trial. Study subjects (N=198) were enrolled from a 
Midwestern academic medical center and were assigned randomly to receive standard care or the 
intervention. Information on depression and pharmacological treatment for depression were 
obtained with other data (e.g., biologic, social, cardiovascular health status) at five time periods 
over one year. Descriptive statistics, t-tests, plots, and regression analysis were used for analysis.   
 The Center for Epidemiologic Studies Depression Scale (CES-D) score mean at baseline 
was 8.94 (SD= 6.55); 42% of the sample were clinically depressed (CES-D Score ≥10). The 
median CES-D scores at baseline were not statistically significantly different between the 
intervention and control groups. Both groups had a decrease in depressive symptoms over time. 
There was not a statistically significant difference in mean CES-D changes scores between the 
intervention and control groups. The patients in the sample were divided into eight groups based 
on treatment group, gender, and baseline pharmacologic treatment. Each group experienced a 
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decrease in depressive symptoms over the course of the study.  Significant variables in the final 
regression model included pharmacologic treatment, income sufficiency, and the Social Support 
Scale. This model accounts for 30% of variance in depressive symptoms in patients with HF.  
 All patients with HF should be screened for depressive symptoms. Health care workers 
should be aware of a patient’s income sufficiency and social support as these may be closely 
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Projections show that the prevalence of heart failure (HF) will increase 46% from 2012 to 
2030, resulting in greater than eight million adults with HF in the United States (Mozaffarian et 
al., 2015). Depression is common among patients with HF with an estimated prevalence rate of 
22% or two to three times that of the general population (Rutledge, Reis, Linke, Greenberg, & 
Mills, 2006). The adverse effects of depressive symptoms on HF patients are documented well 
and include increased cost of care (Welch, Czerwinski, Ghimire, & Bertsimas, 2009), decreased 
health-related quality of life (Gottlieb, 2004; Sharma, Zehtabchi, Rojas, & Birkhahn, 2009), 
decreased adherence to medication regimens (DiMatteo, 2000), increased mortality rates (Jiang 
et al., 2001; van den Broeck et al., 2011), and increased re-hospitalizations (Sherwood et al., 
2011).  
The most recent American Heart Association (AHA) and American College of 
Cardiology HF guidelines stress the importance of providing comprehensive care to HF patients, 
including the assessment and treatment of depression. However, no guidelines or resources on 
how to do so are provided (Hunt et al., 2009; Yancy et al., 2013). The lack of specificity in the 
guidelines reflects the consensus in the research literature; there has been insufficient empirical 
support to guide the treatment of depressive symptoms in adults with HF (Johnson et al., 2012; 
Lane, Chong, & Lip, 2009; Nair, Farmer, Gongora, & Dehmer, 2012; Silver, 2010).   
A systematic review of randomized and non-randomized studies with various 
interventions to treat depression in HF patients revealed that many different patterns in 
depressive symptoms were noted in both intervention and control groups. Some studies found 
that both the intervention and control group had improvements in depression (Fraguas et al., 
 2 
2009; O'Connor et al., 2010; Powell, Calvin, Richardson, & et al., 2010). One home-based 
exercise program study reported improvement in depression in the intervention group; however, 
the results could not be attributed to the intervention directly as this group did not report a higher 
level of physical activity (Jolly et al., 2009). Researchers from one study noted that average 
levels of depression increased slightly during the first stages of the study, but then declined 
substantially by the last measurement period in the study (Flynn et al., 2005). 
This study is a secondary analysis using data from The Self-Management and Care of 
Heart Failure (SMAC-HF) Trial. Smith et al. (2014) reported that the purpose of the SMAC-HF 
trial was to test the effects of multidisciplinary group clinic appointments on the time to first HF 
re-hospitalization or death. In this study, 198 HF patients were assigned randomly either to 
multidisciplinary group clinics focused on HF self-management skills (intervention group) or to 
standard care (control group). Smith et al. (2014) found that multidisciplinary group clinic 
appointments were associated with greater adherence to selected HF medications and longer 
hospitalization-free survival during the time that the intervention was underway. 
Statement of Purpose 
The purpose of this study, using secondary analysis of the SMAC-HF data, was to 
evaluate the prevalence and patterns of depressive symptoms in adults with HF. This study was 
guided by the Biopyschosocial Holistic Model of Cardiovascular Health and was designed to 
accomplish multiple aims: (a) to determine the prevalence of depressive symptoms in a sample 
of HF patients; (b) to determine if there are patterns of depressive symptoms in HF patients; (c) 
to investigate if the patterns of depressive symptoms differ in subjects receiving pharmacologic 
treatment or by gender; and (d) to determine what cardiovascular health markers and the 
biological, psychological, and social factors were associated with depressive symptoms. 
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The long-term goals of this study are to improve understanding of patterns of depressive 
symptoms in HF patients and the factors that are associated with depressive symptom in HF 
patients. This knowledge can help healthcare providers in the assessment and diagnosis of 
depression and guide appropriate treatment. Also, this will aid future research on depressive 
symptoms in HF patients to appropriately design studies and interpret findings.  
Research Questions 
 To meet the aims discussed above, the following research questions will be addressed:  
1) At baseline, what is the prevalence of depressive symptoms, measured by CES-D, in a 
sample of patients with a diagnosis of heart failure who was hospitalized for acute 
decompensation prior to enrollment in the SMAC-HF trial? 
2) At baseline, is there a difference in depressive symptoms between the self- management 
care intervention group and the control group?  
3) What are the patterns of depressive symptoms, measured by CES-D, in heart failure 
patients at five time periods (baseline, 3 months, 6 months, 9 months, and 12 months) for 
the intervention and control groups? 
4) What are the patterns of depressive symptoms, measured by CES-D, in heart failure 
patients at five time periods (baseline, 3 months, 6 months, 9 months, and 12 months) for 
those receiving pharmacologic treatment for depression and those who are not by 
treatment group and gender? 
5) What cardiovascular health markers (i.e., length of HF diagnosis, ejection fraction, and 
Charlson Comorbidity Index), biological factors (i.e., gender, age, and race), 
psychological factors (i.e., antidepressant use) and social factors (i.e., income sufficiency, 
living alone, and social support) were associated with depressive symptoms at baseline? 
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Theoretical Framework 
The theoretical framework guiding this study is the Biopsychosocial Holistic Model of 
Cardiovascular Health (BHMCH). This model states that biological, psychological, and social 
realms interact within each person and are integrated into cardiovascular health (Thomas, 2003). 
The model was selected because it describes the integration of mind and body into 
cardiovascular health status and can guide the assessment and treatment of patients with HF and 
depression. During the development of the model, multiple studies were completed to affirm the 
critical interrelationship between mind and body for cardiovascular health (DeKeyser, Frazier, 
Friedmann, Liehr, & Thomas, 2002; Friedmann et al., 2006; Thomas, Friedmann, Wimbush, & 
Schron, 1997; Thomas & Liehr, 1995). 
In the BHMCH, cardiovascular health interacts with factors in each realm (biological, 
psychological, and social) to affect the other realms. This holistic model, in contrast to a 
biomedical model of disease, posits that acute and chronic shifts in each of the realms affect 
health status, which in turn affects biological, social and psychological factors, including 
depression. The psychosocial factors, including depression, can promote health or disease by 
either moderating or enhancing pathological processes (Thomas et al., 2008). In the 
psychological realm stress, anxiety, and depression diminish health. In the social realm, health is 
promoted by social support (Friedmann et al., 2006). Social and psychological factors affect the 
biological factors. For instance, depression alters levels of cortisol, catecholamines, and 
cytokines; autonomic neurocardiac regulation; and factors that influence cardiac functioning 
(Thomas et al., 2008), creating an interactive non-recursive model. The model (see Figure 1) 
provides the basis for a dynamic interactive approach to the assessment and treatment of 
depression in patients with HF (Thomas et al., 2008). 
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Figure 1. Adapted Biopsychosocial Holistic Model of Cardiovascular Health 
 
Figure 1. Adapted Biopsychosocial Holistic Model of Cardiovascular Health. This model 
features the Biopsychosocial Holistic Model of Cardiovascular Health which depicts the 
relationship between cardiovascular health and the biologic, social, and psychological realms. 
The existing model was adapted to include the variables that will be addressed in this study. 
Adapted from “Depression in Patients with Heart Failure: Prevalence, Pathophysiological 
Mechanisms, and Treatment,” by S.A. Thomas, D.W. Chapa, E. Friedmann, C. Durden, A. Ross, 
M.C.Y. Lee, and H. Lee, 2008, Critical Care Nurse, 28(2), p. 41. Copyright 2008 by American 
Association of Critical-Care Nurses. 
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Definition of Terms 
 Definitions for concepts that are central to the study are provided in the following 
section.  
Heart Failure (HF) 
HF is a complex syndrome with many potential etiologies, diverse clinical features, and 
many clinical subsets. HF is caused by cardiac dysfunction, generally resulting from myocardial 
muscle dysfunction or loss and characterized by either left ventricle dilation and/or hypertrophy 
(Lindenfeld, 2010). Dysfunction can be systolic, diastolic, or both, and leads to neurohormonal 
and circulatory abnormalities resulting in the characteristic symptoms of fluid retention, 
shortness of breath, and fatigue (Lindenfeld, 2010). For the purpose of this study HF will be 
defined as a syndrome in which the heart is unable to fill and/or pump blood sufficiently to meet 
tissue metabolic needs. 
Cardiovascular Health 
 Cardiovascular health is defined as the integration of an individual’s biological, 
psychological and social realms. Cardiovascular health interacts with factors in each realm to 
affect the other realms (Thomas et al., 2008). 
 Ejection Fraction. The ejection fraction (EF) is the fraction of the end-diastolic 
ventricular volume ejected (Butterworth, Mackey, & Wasnick, 2013). More simply stated, EF is 
a measurement of the percentage of blood pumped out of a filled left ventricle with each heart 
beat. 
 Charlson Comorbidity Index. The Charlson Comorbidity Index (CCI) is a method of 
categorizing comorbidities based on diagnoses codes. Each comorbidity category has an 
associated weight, based on the risk of one-year morality. The sum of all the weights results in a 
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single score which indicates the level of comorbidity the patient has (Charlson, Pompei, Ales, & 
MacKenzie, 1987). 
Psychological Factors 
Depression. A major depressive episode consists of five or more symptoms present for 
most of the day for at least two weeks. One of the symptoms must be depressed mood or loss of 
interest in usual activities and symptoms must cause significant distress (Dekker, Peden, Lennie, 
Schooler, & Moser, 2009). Researchers have proposed a continuum of depressive illness that 
ranges from mild depressive symptoms to a diagnosis of major depressive disorder (Dekker et 
al., 2009). Depressive symptoms, such as depressed mood, guilt, hopelessness, low self-esteem, 
fatigue, sleep disturbances, appetite change, and inability to concentrate, are what most 
depression scales actually measure (Dekker et al., 2009).  
Patterns. Patterns of depressive symptoms were evaluated by looking at the trends (i.e., 
increased, decreased, or unchanged levels) of mean symptoms plotted over time (baseline, 3 
months, 6 months, 9 months, and 12 months).  
Pharmacologic treatment. Antidepressant use or pharmacologic treatment for 
depression is defined as patients taking or not taking medication(s) in the antidepressant class of 
medications. 
Biological Factors 
 Biological factors are anything that affects the function and behavior of a living 






Social factors are defined as factors that influence an individual’s lifestyle. The social 
factors included in this study are income sufficiency, whether or not the subject lives alone, and a 
social support scale that includes if the subject has someone to talk to and someone to help them.  
Summary 
The recognition and treatment of depression in HF patients is a problem in healthcare. A 
review of literature revealed many studies addressing depression in HF patients noted patterns 
that were not anticipated. In order to guide future research and practice in this area, a more in-
depth examination of patterns of depressive symptoms in HF patients is needed. To assess the 
patterns of depression in HF patients, a secondary analysis of data from a HF randomized 





This chapter includes an overview of HF, along with studies related to the realms of the 
guiding framework of cardiovascular health: psychological, biological, and social. Studies were 
selected to support the variables included in the study. Studies were identified by searching 
electronic databases and scanning reference lists of articles.  
Background 
Heart Failure and Depression 
HF is a complex syndrome with many etiologies, diverse clinical features, and numerous 
clinical subsets. HF is caused by cardiac dysfunction, generally resulting from myocardial 
muscle dysfunction or loss and characterized by either left ventricle dilation and/or hypertrophy 
(Lindenfeld, 2010). Dysfunction can be systolic, diastolic, or both and leads to neuro-hormonal 
and circulatory abnormalities resulting in the characteristic symptoms of fluid retention, 
shortness of breath, and fatigue (Lindenfeld, 2010). 
On the basis of data from 2009 to 2012, an estimated 5.7 million American adults have 
HF (Mozaffarian et al., 2015). The lifetime risk of developing HF for both men and women at 
the age of 40 is one in five (Mozaffarian et al., 2015). The mortality of HF is high, with 
approximately 20% dying within one year of their diagnosis and a 5-year mortality rate of 59% 
in men and 45% in women (Lloyd-Jones et al., 2010). Cardiac function in HF ranges from no 
apparent symptoms (New York Heart Association [NYHA] class I) to extremely limited function 
(NYHA classes III-IV).  
The incidence of depression in patients with HF is high. Significant depression is 
reported among 22% of patients with HF in general, with estimates of prevalence varying from 
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11% to 35% in the outpatient setting and 35% to 70% in the inpatient setting (Rutledge et al., 
2006). However, the prevalence rates of depression in HF patients have been found to be highly 
variable across studies; this partially could be due to the differences between studies that use 
self-report questionnaires and studies that use diagnostic interviews (Nair et al., 2012). 
The cost of treating patients with HF is high and expected to continue to rise. The total 
cost for HF in 2012 was estimated to be $30.7 billion, with 67% of this cost attributable to direct 
medical costs (Mozaffarian et al., 2015). By 2030 the total cost of HF is projected to increase 
almost 127% to $69.7 billion, which is equal to approximately $244 for every U.S. adult 
(Mozaffarian et al., 2015). 
 Depression is a common, comorbid condition among patients with HF. The World Health 
Organization’s Global Burden of Disease study ranks depression second only to heart disease in 
burden or impact on disability-adjusted life years (WHO, 2008). Researchers have proposed a 
continuum of depressive illness that ranges from mild depressive symptoms to a diagnosis of 
major depressive disorder (Dekker et al., 2009). Depressive symptoms, such as depressed mood, 
guilt, hopelessness, low self-esteem, fatigue, sleep disturbances, appetite change, and inability to 
concentrate, are what most depression scales actually measure (Dekker et al., 2009). Jiang and 
colleagues (2007) reported a “dose effect” for the severity of depression on survival. Even low 
levels of depressive symptoms, typically not considered “clinical depression”, are associated 
with increased mortality rates. The greater the depressive symptoms a HF patient experiences the 
greater the mortality rates (Jiang, 2007). 
 The Diagnostic and Statistical Manual of Mental Disorders (DSM)-V criteria for major 
depressive episode are as follows (Diagnostic and statistical manual of mental disorders, 2013):  
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1) Five (or more) of the following criteria have been present during the same two week 
period and represent a change from previous functioning; at least one of the symptoms is 
either depressed mood or loss of interest or pleasure (note: do not include symptoms that 
are clearly due to a medical condition): (a) depressed mood most of the day, nearly every 
day, as indicated by either subjective report or observation by others; (b) markedly 
diminished interest or pleasure in all, or almost all, activities most of the day, nearly 
every day; (c) significant weight loss when not dieting or weight gain (e.g. a change of 
more than 5% of body weight in a month), or decrease or increase in appetite nearly 
every day; (d) insomnia or hypersomnia nearly every day; (e) psychomotor agitation or 
retardation nearly every day; (f) fatigue or loss of energy nearly every day; (g) feelings of 
worthlessness or excessive or inappropriate guilt nearly every day; (h) diminished ability 
to think or concentrate, or indecisiveness, nearly every day; and (i) recurrent thoughts of 
death, recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific 
plan for committing suicide. 
2) The symptoms cause clinically significant distress or impairment in social, 
occupational, or other important areas of functioning. 
3) The episode is not attributable to the direct physiological effects of a substance or 
another medical condition. 
4) The major depressive episode is not better accounted for by schizoaffective disorder 
and is not superimposed on schizophrenia, schizophreniform disorder, delusional 
disorder, or psychotic disorder not classified elsewhere. 
 5) There has never been a manic episode or a hypomanic episode (Diagnostic and 
statistical manual of mental disorders, 2013). 
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 Measuring depression. Varied methods are used to determine the presence of 
depressive symptoms in research literature. Depressive symptoms screening is conducted with 
the use of self-rated survey instruments; however, the self-rated reports are not meant to be 
diagnostic of depression. Few studies can afford the time and/or personnel needed to complete 
the diagnostic interview that is required for the determination of a diagnosis of depression. 
Consequently, depressive symptom screening scales are frequently used in the research setting 
(Delville & McDougall, 2008). Screening scales are necessary because the Structured Clinical 
Interview (SCI) for diagnosing psychiatric disorders takes specially trained mental health 
professionals, as well as one to two hours to complete.  
A systematic review of 16 studies of the instruments used and incidence of depression in 
HF patients found that 11 studies used screening instruments only, three used both a screening 
instrument and a diagnostic interview, and two used only a diagnostic interview (Delville & 
McDougall, 2008). Screening instruments were found to result in higher frequencies of 
depressive symptoms (21-60%) when compared to diagnostic interviews (14-39%). Another 
meta-analytic review addressing the prevalence of depression in HF patients found the majority 
of studies used depressive symptoms inventories as opposed to clinical interviews (Rutledge et 
al., 2006). One study found that participants were able to identify by self-report many causative 
factors of depression, and additional factors were identified by a psychiatric nurse specialist, 
allowing for individualized diagnoses and treatment (Bowden et al., 2011). 
The relationship between depression and heart failure. The interaction between 
depression and HF is understood incompletely despite extensive research (Nair et al., 2012). 
There appears to be a bi-directional relationship between depression and HF.  High rates of 
depression in HF patients could be explained either by individuals with depression having a 
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greater risk for HF or HF patients having a greater risk for depression. It is likely that HF and 
depression create a cycle in which they exacerbate each other, with the combined effects being 
more severe than the additive effects of each state alone (Nair et al., 2012). 
Depressed patients in the Systolic Hypertension in the Elderly Program were twice as 
likely as non-depressed patients to develop HF that was not mediated by myocardial infarction 
(Abramson, Berger, Krumholz, & Vaccarino, 2001). This was supported by a retrospective study 
(n= 236,079 with no baseline cardiovascular disease) that found when compared with unaffected 
patients, those with anxiety only, Major Depressive Disorder (MDD) only, and both disorders 
were at increased risk for incident HF in age-adjusted models (hazard ratio [HR] = 1.19, (95% 
confidence interval [CI]= 1.10-1.28); HR= 1.21, (95% CI = 1.13-1.28); and HR= 1.24, (95% CI 
1.17-1.32); respectively (Garfield et al., 2014). Another study found that HF more than doubles 
the risk of new-onset depression (Luijendijk et al., 2010).  
There are four pathological patterns that occur in depressed patients, which correspond to 
the pathogenesis of heart failure: neuro-hormonal activation, hypercoagulability, autonomic 
neuro-cardiac dysfunction, and cytokine release (Brown, Varghese, & McEwen, 2004; Joynt, 
2004; Thomas, 2003). The authors suggest that the pathological changes mediate the risk for 
cardiac events with a subsequent poor prognosis in patients with HF who are depressed. 
Behavioral actions likely affect the interaction between HF and depression as well. Patients with 
depression exhibit many behaviors that may contribute to the development and worsening of HF; 
they are less active, less adherent with medication regimens and diet, and more likely to abuse 
drugs and alcohol (Nair et al., 2012).  
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 The adverse effects of depressive symptoms in heart failure. The adverse effects of 
depressive symptoms in patients with HF are documented well in literature. More than two 
dozen studies have shown depression to be an important risk factor for morbidity and mortality 
in HF patients, independent of physiologic measures of disease severity (Fulop, Strain, & Stettin, 
2003; Go et al., 2014; Jiang et al., 2001; Murberg & Furze, 2004; Rozzini, Sabatini, Frisoni, & 
Trabucchi, 2002; Rumsfeld et al., 2003; Westlake, Dracup, Fonarow, & Hamilton, 2005). 
Patients with HF who had depression were more than twice as likely as those without depression 
to die or be re-hospitalized within three months to one year after hospitalization (Jiang et al., 
2011). A seven-year follow-up study of patients with HF found that those with depressive 
symptoms at baseline were more likely to die than those without depressive symptoms; the risk 
of death increased by level of depressive symptoms: 21% with mild, 53% with moderate, and 
83% with severe (Jiang, 2007). 
 Patients who have concurrent HF and depression have increased medical costs of 25 to 40 
percent (Nair et al., 2012). It is estimated that depression and psychological impairment may be 
responsible for nearly 25% of the cost associated with treating HF (Mann, 2011). In a sample of 
784 patients with HF, depression was found to increase the number of hospitalizations by 50% 
after controlling for physician adherence to evidence-based medications and HF severity 
(Johnson et al., 2012). Depression was associated with poor compliance with medical regimens, 
which has significant consequences for HF patients (Mann, 2011). 
The problem of depression in adults with HF is well documented. Despite this problem, 
there is little research to guide the treatment of depression in this population. The lack of 
research to guide the assessment and treatment of depression in the HF population leads to 
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under-diagnosis and under-treatment (Bean, Gibson, Flattery, Duncan, & Hess, 2009; 
Connerney & Shapiro, 2011; Sullivan et al., 2009).  
 Pharmacological treatment for depression. The data reporting the safety and efficacy 
of antidepressant use in patients with HF is limited. Many antidepressant drugs have known 
cardiovascular side effects, and no randomized clinical trials have provided the evidence 
necessary to support the use of pharmacologic treatment (Johnson et al., 2012). Smith and Book 
(2001) state that tricyclic antidepressants (a class of antidepressant drugs that inhibit the uptake 
of both norepinephrine and serotonin) should be avoided in patients with cardiovascular disease, 
due to the risk of life-threatening arrhythmias. This risk is increased in patients already taking 
medications that can prolong the QT interval (Tousoulis et al., 2010). Tricyclic antidepressants 
generally are contraindicated in patients following myocardial infarction, and this class of 
antidepressant can impair left ventricular function in patients with severe systolic dysfunction 
(Smith & Book, 2011). Monoaminoxidase inhibitors have known adverse effects, including 
orthostatic hypotension and increased risk of hypertensive crisis, which would discourage the use 
of this medication class in patients with HF (Tousoulis et al., 2010). 
 Selective serotonin reuptake inhibitors (SSRIs) as a class combine safety and efficacy, 
and are associated with a lower rate of adverse cardiovascular events. However, SSRIs still have 
adverse effects including increased bleeding risk due to platelet suppression (Tousoulis et al., 
2010). SSRIs rarely have been associated with orthostatic hypotension and bradycardia and do 
not appear to depress cardiac function (Smith & Book, 2011). The SSRIs can affect the 
cytochrome P450 system, potentially altering the metabolism of drugs that heart failure patients 
may be using including antiarrhythmic medications, beta blockers, and Coumadin (Smith & 
Book, 2011). One review of studies found tricyclic antidepressants and SSRIs were associated 
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with similar rates of major adverse cardiovascular events, but other cardiovascular side effects 
were more commons with tricyclic antidepressant use (Swenson, Doucette, & Fergusson, 2006). 
A majority of the pharmacologic interventions included antidepressants in the SSRI class 
(paroxetine, sertraline, and citalopram). One study reported that SSRIs might have a beneficial 
effect on endothelial function and nitric oxide bioavailability (Tousoulis et al., 2010). Paroxetine 
CR was shown to significantly improve depression when compared to a placebo group (Gottlieb 
et al., 2007). Of note, six patients (43%) in the placebo group experienced deterioration, with an 
increase in Becks Depression Inventory (BDI) scores, while only one (7%) in the active 
treatment experienced this problem (p= .03). The reduction in depression was accompanied by 
improvements in the psychological aspects of quality of life. Gottlieb et al (2007) also found a 
significant association between the reduction in depression and improvement in social function 
in placebo patients. Both citalopram (Fraguas et al., 2009) and sertraline (O'Connor et al., 2010) 
were noted to have high placebo rates that could possibly be associated with the support from 
psychiatric and nursing attention; no significant difference between intervention or placebo 
groups were found. In the sertraline trial, it was considered that the level of depression in the 
study might not have been severe enough to respond to therapy. Both citalopram and sertraline 
were tolerated well with few side effects reported. 
 Other interventions. Beyond pharmacologic options, exercise, complementary 
medicine, and behavioral interventions have been used to treat depression in HF patients. To 
determine the effects of psychological interventions for treating depression in adults with HF, the 
most recent Cochrane Review reported that no completed studies met the inclusion criteria. The 
main reasons for exclusion included lack of suitability of study design or intervention, not 
randomized, no appropriate control group, incomplete randomization, no useful outcome data, 
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and combined interventions (Lane et al., 2009). Despite this, the review of observational 
studies suggested that psychological interventions in patients with HF do reduce symptoms of 
depression, and that randomized controlled trials are needed in this area (Lane et al., 2009). 
Researchers (Woltz et al., 2012) conducting a more recent systematic review addressing the 
effects of interventions on depression in HF patients reported that despite some evidence for 
different pharmacologic and complementary medicine strategies, the review did not support the 
development of guidelines for the treatment of depression in HF patients due to lack of sufficient 
evidence. 
Treatment of depression in HF patients has the potential to improve quality of life, 
mortality and morbidity, and decrease the cost of healthcare and re-hospitalizations. Despite the 
lack of guidelines for treatment of depression in HF patients, there have been a few studies with 
promising outcomes. Jiang et al. (2011) found that patients who experience remission from 
depression have significantly lower cardiovascular events than those who did not experience 
remission. Gottlieb (2004) demonstrated that effective treatment of depression in HF patients 
reduced the medical costs of HF. The average cost of one HF hospitalization in 2004 was $9,400, 
and the aggregate cost of a HF-related hospitalization was $10.4 billion (Johnson et al., 2012). 
Hospitals now are being penalized for avoidable hospitalizations and readmission by the Centers 
for Medicare and Medicaid Services (Yancy et al., 2013). 
 Patterns of Depression. A review of literature revealed many different patterns of 
depressive symptoms were noted in both intervention and control groups of clinical trials. Some 
studies found that both intervention and control groups had improvements in depression (Fraguas 
et al., 2009; O'Connor et al., 2010; Powell et al., 2010). Fraguas et al. (2009) completed a study 
to investigate the effectiveness of citalopram treatment for major depressive disorder (MDD) in 
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elderly patients with HF. The subjects of the study included 72 older outpatients with EFs less 
than 50% and diagnosed with MDD by means of the structured clinical interview using the 
DSM-IV. The study was an eight-week, double-blind treatment using the 31-item Hamilton 
Rating Scale for Depression (HAM-D-31) and Montgomery Asberg Depression Rating Scale 
(MADRS) to detect depression; additionally the Systematic Assessment for Treatment Emergent 
Effects was administered to monitor for adverse effects. The MADRS scores showed a trend (p= 
.082) towards superiority of citalopram when compared to placebo, but no differences for the 
HAM-D scores. In both groups, patients had significant (p< .001) decreases in depressive 
symptoms that led to the study being concluded early with only 37 patients (Fraguas et al., 
2009). The authors concluded the findings possibly were due to weekly psychiatric follow-up, 
including counseling, for both groups.  
Another example, O’Connor et al. (2010) tested the hypothesis that HF patients treated 
with sertraline would have lower depression scores and fewer cardiovascular events when 
compared with placebo. This was a randomized, double-blind, placebo-controlled trial of 
sertraline (dose= 50 to 200mg/day) versus placebo for 12 weeks (O'Connor et al., 2010). 
Subjects were greater than 45 years old, were diagnosed with clinical depression, and not using 
antidepressants. This randomized controlled trial found that antidepressants did not result in a 
significant improvement in depression when compared to the placebo. However, the intervention 
and placebo group both experienced a considerable reduction in depressive symptoms that was 
attributed to both groups receiving a nursing intervention. Also, it was considered that the 
baseline level of depression for the subjects in the study might not have been severe enough to 
respond to sertraline therapy. 
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Powell et al. (2010) completed a randomized clinical trial (RCT) to determine the value 
of self-management counseling plus HF education, when compared with HF education alone on 
time to HF hospitalization. Depression, measured by the Geriatric Depression Scale (GDS), was 
a secondary outcome. The RCT included 902 patients who were randomized to one of the 
groups, HF education alone or HF education plus self-management counseling, and provided 
education over one year with follow-up between two to three years. At baseline, major 
depressive symptoms were evident in 29% of the sample. Major depressive symptoms decreased 
from 136 to 90 (20%) in the self-management group and from 129 to 99 (22%) in the education 
group (p= .008 for time effect). Compared with an enhanced educational intervention alone, the 
addition of self-management counseling did not reduce death or HF hospitalization in patients 
with mild to moderate HF. However, the authors did identify that the education component given 
to both groups appeared to have been a more active treatment than expected. 
 Riegel et al. (2006) completed a RCT to test the effectiveness of telephone case 
management in decreasing hospitalizations and improving health-related quality of life and 
depression in HF patients of Hispanic or Mexican origin. Hispanics with chronic HF (n= 134) 
were randomized to the intervention or usual care. Depression was assessed with the Patient 
Health Questionnaire (PHQ-9) at baseline, three months, and six months. At baseline, 10 (7.9%) 
were on antidepressant therapy. No significant group changes were founds in HF 
hospitalizations, HF readmission rates, HF days in the hospital, HF cost of care, all-cause 
hospitalizations or cost, mortality, health-related quality of life, or depression. Improvement in 
PHQ scores were noted in both groups, but there was no significant difference between groups 
from baseline to three and six months in terms of depression scores (Usual care: 8.6±5.4; 
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2.3±2.3; 2.0±2.1; and Intervention 8.8±5.8; 1.9±2.1; 1.5±2.1; respectively) (Riegel, Carlson, 
Glaser, & Romero, 2006). 
Another pattern noted was improvement of all patients with minor depression, despite 
group assignment (Gary, Dunbar, Higgins, Musselman, & Smith, 2010). Gary et al. (2010) 
completed a RCT with repeated measures to compare the effectiveness of a combined 12-week 
home-based exercise/cognitive behavior program (EX/CBT) to a group receiving cognitive 
behavioral program (CBT) alone, a group receiving home-based exercise (EX) alone, and a usual 
care (UC) group. Of the sample, the majority (77%) reported a prior episode of major depressive 
disorder (MDD), and 29% were on antidepressants. Only the combined EX/CBT group 
demonstrated a sustained reduction in depression scores. The greatest reduction in HAM-D 
scores over time occurred in the EX/CBT group (-10.4), followed by CBT (-9.6), EX (-7.3), and 
UC (-6.2), but none were statistically significant (Gary et al., 2010). It was noted that all patients 
who had minor depression (HAM-D scores between 11-14) improved over time despite group 
assignment, indicating that interventions may not be needed in this group of patients. Patients on 
antidepressants had no better outcomes than those who were not taking them. 
In a RCT, Jolly et al. (2009) aimed to assess the effectiveness of a home-based exercise 
program in addition to specialist HF nurse care compared to specialist HF nurse care alone. This 
home-based exercise program study reported improvement in depression in the intervention 
group; however, the results could not be attributed to the intervention directly as this group did 
not report a higher level of physical activity (Jolly et al., 2009). The groups were not similar at 
baseline, the exercise group was younger, had higher Hospital Anxiety and Depression Scale 
(HADS) depression scores, and lower systolic blood pressure at baseline. Approximately a 
quarter of participants scored as having possible or probable depression on the HADS at 
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baseline, so there was some potential for improvement (Jolly et al., 2009).  No statistically 
significant difference between groups were noted on the primary outcome, the Minnesota Living 
with HF Questionnaire, but depression scores improved in treated patients compared with control 
subjects at 12 months (6.26 vs 5.50, respectively; p= .002). However, at 12-month follow up the 
exercise group did not report a higher level of physical activity; thus, this does not explain the 
lower level of depression. 
One study noted that average levels of depression increased slightly during the first 
stages of the study, but then declined substantially by the last measurement time period in the 
study (Flynn et al., 2005). Flynn et al. (2005) completed a treatment-only pilot study to examine 
whether a yearlong group-based, self-management intervention was feasible, and if it could 
improve self-management skills in patients with HF. At baseline 52% of the sample had scores 
of 10 or higher on the Beck Depression Inventory (BDI), indicating at least mild levels of 
depression. Average levels of depression increased slightly during the first stages of the study, 
but they declined substantially by the end of the year with only 20% of patients with at least mild 
depressive symptoms (Flynn et al., 2005). The intervention group, when compared to baseline, 
had increases in overall self-efficacy in practicing self-management skills (p<.001) and in four 
out of five specific self-management skills. Compared with baseline levels there was a 
significant decrease in depressive symptoms (9.9±5.0 to 7.3±5.0, respectively; p< .001). 
Other patterns were noted as well. Martensson et al. (2005) completed a RCT to 
determine the effects of a nurse-led intervention to improved self-management of patients with 
HF in a primary care setting regarding health-related quality of life and depression, measured by 
Zung Self-Rating Depression Scale (SDS). There was no significant change in mean differences 
between the two groups at baseline, three month, or twelve month follow-ups. There was no 
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significant median difference in SDS between the two groups. Using cut-off scores from the 
SDS revealed that there was a significant difference in moderate and severe depression (p= .02) 
from baseline to three-month follow-up with the intervention group having significantly less 
depression (Mårtensson, Strömberg, Dahlström, Karlsson, & Fridlund, 2005). However, at 
twelve-month follow-up there was no difference between the groups. 
 Sullivan et al. (2009) in the Support, Education, and Research in Chronic Heart Failure 
(SEARCH) study demonstrated that a mindfulness-based, psycho-educational intervention 
successfully reduced anxiety and depression at six months, but the effect was attenuated at one 
year (Sullivan et al., 2009). This was a prospective cohort study that was designed to assess the 
impact of a mindfulness-based, psycho-educational intervention on clinical outcomes, depression 
and quality of life, in a sample 208 adults diagnosed with HF with EF less than forty percent. 
Subjects in the study had a mean age of 61 years, left ventricular rejection fraction of 26%, and a 
median NYHA classification of II (Sullivan et al., 2009). It was noted that the treatment group 
was more depressed at baseline. Over time when compared with controls, treatment results 
showed lower anxiety and depression, along with improved symptoms, and clinical scores. There 
was no treatment effect on death or rehospitalization at one year. Scores improved in treated 
patients when compared with control subjects from baseline to three months (-1.74 vs. 0.46, p= 
.01) and from baseline to six months (-1.37 vs. 0.90, p= .01). However, both groups had 
improved scores, thereafter, so the treatment impact was attenuated. A possible bias in this study 
was that 80% of patients in both groups were managed by one cardiology practice. 
Biopsychosocial Holistic Model of Cardiovascular Health 
 Variables of interest that represent the Biopsychosocial Holistic Model of Cardiovascular 
Health will be discussed based on the domains of the model (see Figure 1, p. 5). These domains 
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include cardiovascular health, the psychological realm, the biological realm, and the social 
realm.  
Cardiovascular Health 
 The factors that represent cardiovascular health include: (a) length of HF diagnosis, (b) 
EF, and (c) Charlson comorbidity index. Studies relevant to each of these variables are presented 
below. 
 Length of heart failure diagnosis. Only two studies were identified that discussed 
length of HF diagnosis and depression. One study, a dissertation, reported that there was no 
statistically significant difference in mean depression scores by length of time living with HF 
(Larsen, 2010). Another study noted higher levels of depression in those who had been 
diagnosed with HF for over a year (Polikandrioti et al., 2010). 
 Ejection Fraction. Two large HF studies found that EF did not differ between subjects 
with depression (BDI ≥ 10) and those without depression (Gottlieb, 2004; Gottlieb et al., 2009). 
A more recent study (n= 268) also reported that EF was not related to depression over time in the 
HF population (Brouwers et al., 2014). 
 Charlson Comorbidity Index. No studies were found in literature review specifically 
discussing the relationship between comorbidity and depression in HF patients. Despite this lack 
of discussion, many studies did measure and control for comorbidity in their analysis (Dunagan 
et al., 2005; Riegel et al., 2006). 
Psychological Realm 
 Variables representing the psychological realm include depressive symptoms and 
pharmacologic treatment for depression. Studies about these topics have been discussed in 
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previous sections above (depression and heart failure, pp. 9-22; and pharmacological treatment 
for depression, pp. 15, 16). 
Biological Realm 
 Variables of interest in the biological realm include demographic characteristics: (a) 
gender, (b) age, and (c) race. Studies relevant to each of these variables are presented below. 
 Gender. The annual rates per 1000 population of new HF events for white men are 15.2 
for those 65 to 74 years of age, 31.7 for those 75 to 84 years of age and 65.2 for those greater 
than or equal to 85 years of age; for white women in the same ages groups the rates are 8.2, 19.8, 
and 45.6, respectively (Go et al., 2014; Mozaffarian et al., 2015). Women made up more than 
half of older adults and had unique risk factors and differences in the clinical manifestations of 
HF symptoms when compared to men with HF (Hoppe & Hermann, 2003). Consistent with the 
trends in the general population, one study found that women with HF had significantly worse 
depression scores than men (Gottlieb, 2004). This finding is not reported consistently; a more 
recent study (Kao et al., 2014) of 147 HF patients found that about two-thirds of both male and 
female patients had significant depressive symptoms (Becks Depression Inventory II score 
greater than or equal to 14). The study did report that females were more likely to have moderate 
or severe depressive symptoms when compared to males.  
 Age. HF is principally a disorder of older adults with the prevalence and incidence rates 
increasing dramatically with age. The prevalence of HF increase with age, from less than 1% in 
the 20-39 year age group to more than 20% in people age 80 years or older (Mann, 2011). The 
incidence of HF increases with age, doubling with each successive decade above age 45 for both 
men and women (Mann, 2011). Older patients with HF have a particular propensity for 
developing HF with preserved left ventricular systolic function or normal EF. Population-based 
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reports suggest that more than half of elderly patients with HF have normal EFs and that 
proportion increases with age (Mann, 2011). Mortality rates from HF increase with age and are 
threefold higher in patients aged 65 to 74 in comparison to those aged 25 to 54 years (Mann, 
2011).  
 Older adults with HF have chronic exercise intolerance, frequent hospitalizations, and 
high health care costs. Older adults with HF exhibit higher levels of depression than healthy 
older adults, with almost three quarters of those with HF having depressive symptoms (Moser et 
al., 2010) . Older adults tend to suffer from subsyndromal or atypical depression that is difficult 
to diagnose and can be as distressing and disabling as major depression (Ahmed, 2004). Upon 
hospital admission, elderly patients having HF and depressive symptoms was associated with 
decrease in functional status at six months, death at three months, six months, and one year, and 
hospital readmissions at three months and one year (Jiang et al., 2001; Vaccarino, Kasl, 
Abramson, & Krumholz, 2001). Depressed elders made two to four times as many outpatient 
medical visits as elders who were not depressed (Fulop et al., 2003). Additionally, older adults 
frequently were underrepresented in HF clinical trials (Mann, 2011). 
 Race. HF disproportionately affects African Americans, who have greater financial 
burden, present with symptoms at younger ages, and are less likely to receive evidence-based 
medical treatment when compared to other races (Bibbins-Domingo, 2009; Peterson & Yancy, 
2009). There are multiple factors that have been postulated to play a role in the increased 
prevalence including: a higher burden of risk factors like hypertension, a genetic predisposition 
to cardiomyopathy, and exposures to toxins such as drugs and alcohol (Roger et al., 2012; 
Schocken, 2008; Yancy, 2005). The age-adjusted incidence rate of HF per 1000 person-years is 
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3.4 for Caucasian women, 6.0 for Caucasian men, 8.1 for African American women, and 9.1 
for African American men (Loehr, Rosamond, Chang, Folsom, & Chambless, 2008).  
 African Americans are likely to have more severe or disabling depressive disorder than 
individuals of Caucasian or Hispanic ethnicity (Sharma et al., 2009). There is limited evaluation 
of depression and HF in ethnic groups; some studies have found an increased prevalence of 
depression in African Americans with HF when compared to other races (Evangelista, Ter-
Galstanyan, Moughrabi, & Moser, 2009; Gottlieb et al., 2009; Nair et al., 2012). Other studies 
have found no difference by race (Albert et al., 2009; Bean et al., 2009). 
Social Realm 
 Within the social realm, factors included are: income sufficiency, living along, and social 
support (i.e., someone to talk with and someone to help). Studies will be discussed in each of 
these areas. 
 Income sufficiency. Only one study specifically discussed income level in relation to 
depressive symptoms in HF patients. Havranek in 2004 found four predictors of the development 
of depressive symptoms in HF patients: living alone, financial burden from medical care, alcohol 
abuse, and health status measured by the Kansas City Cardiomyopathy Questionnaire.  
 Living alone. One study found no difference in patients with depression (Becks 
Depression Inventory Score ≥ 10) among those who live alone or those who lived with others 
(Gottlieb, 2004). However, another study (Havranek, 2004) reported that patients who developed 
depressive symptoms were nearly more than twice as likely to live alone than those who did not 
(40.4% vs 22.9%, p = .02). 
 Social Support. One study (Chung, Lennie, Dekker, Wu, & Moser, 2011) reported that 
poor social support from family, friends, and health care providers may play a role in worsening 
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health outcomes and quality of life in patients with HF. Chung et al. (2011) found that 
depressive symptoms and poor social support had a synergistic, negative effect on event-free 
survival in HF patients. Another recent study demonstrated that social support predicts changes 
in depression over time; patients in this study with low social support at baseline had increased 
depression over two years (Friedmann, Heesook, Thomas, Chapa, & Hyeon Joo, 2014). Another 
study reported that social support was a predictor of depressive symptoms, and further elaborated 
on the relationship by stating that social support mediated the relationship between HF physical 
symptoms (Heart Failure Symptom Survey) and depressive symptoms (Graven et al., 2015). 
 There are two main models, physiologic and behavioral, that explain how social support 
effects health outcomes. The physiologic model purports that social support provides a 
generalized positive affect that suppress the harmful neuroendocrine response to negative 
emotions such as depression and stressful events (Luttik, Jaarsma, Moser, Sanderman, & van 
Veldhuisen, 2005). Good social support can provide protection from stress and suppress the 
neuroendocrine system response. The behavioral model states that social support can influence 
health behaviors, which in turn affect health outcomes. Heart failure patients with social support 
may be more consistent with their medication and lifestyle changes, while those who are socially 
isolated may have difficulty changing harmful behavioral patterns (Luttik et al., 2005). 
Summary 
 In summary, depression in patients with HF is a complex and commonly occurring 
problem. The combination of depression and HF lead to worsened health outcomes. However, it 
is likely these can be improved with the diagnosis and treatment of depression in this patient 
population. This study provides a more in-depth look into depressive symptoms in a group of 
individuals with HF. First, the knowledge gained in this study can guide health care providers in 
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identifying and treating depression in HF patients. Second, it can guide researchers by 
providing knowledge of possible patterns through use of repeated measures as well as the 





To better understand the prevalence and patterns of depressive symptoms in adults with 
HF the following five research questions will be addressed.  
1) At baseline, what is the prevalence of depressive symptoms, measured by CES-D, in a 
sample of patients with a diagnosis of heart failure (HF) who was hospitalized for acute 
decompensation prior to enrollment in the SMAC-HF trial? 
2) At baseline, is there a difference in depressive symptoms between the self- management 
care intervention group and the control group?  
3) What are the patterns of depressive symptoms, measured by CES-D, in heart failure 
patients at five time periods (baseline, 3 months, 6 months, 9 months, and 12 months) for 
the intervention and control groups? 
4) What are the patterns of depressive symptoms, measured by CES-D, in heart failure 
patients at five time periods (baseline, 3 months, 6 months, 9 months, and 12 months) for 
those receiving pharmacologic treatment for depression and those who are not by 
treatment group and gender? 
5) What cardiovascular health markers (i.e., length of HF diagnosis, ejection fraction, and 
Charlson Comorbidity Index), biological factors (i.e., gender, age, and race), 
psychological factors (i.e., antidepressant use) and social factors (i.e., income sufficiency, 
living alone, and social support) were associated with depressive symptoms at baseline? 
 
This chapter describes the research design, the study sample and setting, the measurement 




This correlational study uses a secondary data analysis to evaluate the prevalence and 
patterns of depressive symptoms in adults with HF. Secondary data analysis provides the 
advantage of resource savings and cost effectiveness, as the data already collected included a 
depressive symptom measure that will likely be adequate to answer the proposed research 
questions.  
The purpose of the original randomized, controlled clinical trial was to test the effects of 
multidisciplinary group clinic appointments for individuals with HF on the primary outcome of 
time to first HF rehospitalization or death (Smith et al., 2014). Depression, as well as many 
factors known to be associated with depression, were measured at five time points in this study, 
and the sample was from the target population, making this study a suitable fit for the proposed 
secondary data analysis. As is important when considering the suitability of secondary data 
analysis, the parent study: (a) produced high quality data with recently published findings, (b) 
utilized a research protocol, (c) had standard operations, and (d) had a codebook for the data set 
(Doolan, 2009).  This study focused on the prevalence of depressive symptoms, differences 
between the intervention and control group, patterns over five time points over the course of a 
year, differences between those receiving pharmacologic treatment by intervention group and by 
gender, and what factors were associated with depressive symptoms. 
Sample 
Patients hospitalized for an exacerbation of HF were enrolled into a randomized 
controlled clinical trial of multidisciplinary group clinic appointments between March 2007 and 
April 2011. They were identified by a daily admission records review at a Midwestern academic 
medical center. Patients were hospitalized with HF and classified as New York Heart 
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Association (NYHA) Functional Classification III or IV, regardless of EF. Criteria for 
exclusion included: (a) evidence of transient, reversible HF, (b) a planned heart transplant, (c) 
end-stage renal disease (serum creatinine > 4mg/dl), (d) unresected malignancy or other terminal 
illness, (e) discharged to a nursing home, rehabilitation unit, or extended care facility, (f) any 
condition that would prevent engagement in the intervention including blindness, deafness, 
dementia, cognitive deficiency, or (g) could not write and speak English (Smith et al., 2014).  
The NYHA classification system frequently is used in research during selection and 
stratification of subjects as well as the measurement of research outcomes (Bennett, 2002; Faller 
et al., 2009; Pressler et al., 2011; Rohyans & Pressler, 2009). Class III are patients that: (a) have 
cardiac disease resulting in marked limitation of physical activity, (b) are comfortable at rest, or 
(c) less than ordinary physical activity causes fatigue, palpitation, dyspnea, or anginal pain. Class 
IV patients have: (a) cardiac disease resulting in the inability to carry on any physical activity 
without discomfort, (b) symptoms of HF or  (c) anginal syndrome that may be present even at 
rest, if any physical activity is undertaken the discomfort increases (Bennett, 2002). Only those 
subjects that were identified as Class III or IV were included in this study.  
A total of 774 patients were found to meet the criteria for enrollment; of these 198 (26%) 
were enrolled. The top reasons for not enrolling in the study were patients were “not interested” 
or they were unable to be reached by study personal within two weeks of discharge. A total of 
198 study subjects were placed into blocks of four to eight subjects based on time of enrollment; 
then the blocks of subjects were assigned randomly to receive standard care (n= 106) or 
intervention (n= 92). Of the 198 patients in the parent study, 15.15% (n= 30) withdrew over the 
course of the study from baseline to 12 months. The reasons for withdrawal were as follows: 
died (n= 18), lost contact (n= 9), new illness (n= 2), and too busy (n= 1) (Piamjariyakul, 2015). 
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Setting 
Subjects were recruited and enrolled from a cardiology clinic at a Midwestern academic 
medical center affiliated hospital. The intervention subjects had group appointments at a building 
attached to the hospital in which they were recruited. 
Procedures 
 Prior to subject recruitment for the primary study, Institutional Review Board (IRB) 
approval was obtained. IRB approval for non-human subject research approval was obtained 
prior to the de-identified data being provided by the original research team. Data were 
transferred through secure email and kept on a secure computer for this study. Nurses with 
special training in the area of trial enrollment procedures completed the informed consent and 
baseline data collection (Smith et al., 2014). Double entry of data by independent operators with 
comparison to verify accuracy was completed. Also, to verify accuracy of the medical record 
data, three people recorded and reviewed the data. Patients were enrolled during or within two 
weeks following hospitalization.  
 During and after hospitalization, health care and HF treatment teams continued treating 
both arms of the study (Smith et al., 2014). The SMAC-HF intervention included four weekly 
group visit appointments and a booster appointment at six months. Each group visit included the 
following multidisciplinary team: a nurse practitioner with HF experience, a mental health 
clinical nurse specialist, a social worker, a counselor, and a dietician (Smith et al., 2014). The 
depression screening was obtained with other data at the beginning of each group clinic 
appointment. The control patients had follow-up data collection at the same time intervals as the 
intervention group. Patients in both group assignments were given a short HF DVD series to 
standardize the education information across both groups (Smith et al., 2014). To reduce subject 
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risk, the parent study protocol included a referral for all patients with severe depression (CES-
D score of 20 or greater) for consultation with a psychiatric Clinical Nurse Specialist.  
During the course o the study 75 subjects were referred to a mental health clinical nurse 
specialist due to CES-D scores of greater than 20 (Piamjariyakul, 2015). The topics discussed in 
the referrals including situational grief or depression over limitations in functional capacity or 
role reversal, anger or regret associated with chronic illness, psychiatric problems with new 
diagnosis, family issue including lack of support, and financial problems. The follow-up 
counseling that was provided included coping strategies, referral to a physician for initiation or 
adjustment of psychiatric medications, and referral to mental health agencies (Piamjariyakul, 
2015). 
Measures 
The Biopsychosocial Holistic Model of Cardiovascular Health (BHMCH) and review of 
literature were used to select variables that were addressed in this study. Variables representing 
the psychological, biological, and social realms, as well as the measures of overall cardiovascular 
health, were selected for inclusion in this study. 
Heart Failure 
In the proposed study, HF was measured by: patients hospitalized with NYHA class III or 
IV HF, but not required to have a reduced left ventricular ejection fraction (EF). 
Dependent Variable/Psychological Realm 
 Two variables from the psychological realm, depressive symptoms and pharmacologic 
treatment for depression, were included in this study.  
Depressive symptoms. Depressive symptoms, the dependent variable in the study, were 
measured by the short Center for Epidemiologic Studies Depression Scale (CES-D) (See Table 
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1). The short CES-D is a self-administered 10-item scale commonly used to measure 
depressive symptoms (see Appendix A). The scale was developed for use in the general 
population in studies of epidemiology of depressive symptoms (Radloff, 1977). The intended 
purpose of the scale is to measure the current level of depressive symptoms with an emphasis on 
the affective component, depressed mood; it should be noted that it is not intended to be used for 
diagnosis (Radloff, 1977). The CES-D measured depressive symptoms experienced over the past 
four weeks, making it time sensitive and more likely to detect reactive or situational depression. 
Responses were ranked using a Likert-type scale with responses ranging from zero (less than one 
day a week) to three (five to seven days a week). Response scores were summated and the final 
score ranged from 0 to 28 with higher scores reflecting greater levels of depressive symptoms 
(Ancheta et al., 2009). Generally a score of greater than 16 is used to define patients at risk for 
clinical depression in the CES-D 20 item, the value of greater than or equal to 10 has been 
proposed for the CES-D 10 item (Andresen, Malmgren, Carter, & Patrick, 1994; Jaarsma et al., 
2010). 
Initial testing of the scale demonstrated high internal consistency (α = 0.85), acceptable 
test-retest stability (r = 0.45 to 0.70), strong concurrent validity by clinical and self-report 
criteria, and substantial evidence of construct validity (Radloff, 1977). The short CES-D 10-item 
questionnaire has been validated against the full-length 20-item CESD and shown to have good 
predictive accuracy (kappa= 0.97, p < .001) (Andresen et al., 1994; Furukawa et al., 1997; 
Kohout, Berkman, Evans, & Cornoni-Huntley, 1993). The CES-D successfully has been used to 
screen for depressive symptoms in heart failure patients (Ancheta et al., 2009; Bowden et al., 
2011; Lesman-Leegte, Jaarsma, Sanderman, Hillege, & van Veldhuisen, 2008; Sullivan et al., 
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2009; van den Broeck et al., 2011) and is sensitive to changes in depressed mood over time 
(Park, Fenster, Suresh, & Bliss, 2006). 
Reliability analysis was completed on the CES-D scale at each time point it was 
administered for this study. In the secondary data analysis, the CES-D 10 scale had a high 
internal consistency at all time points during this study as measured by Cronbach’s alpha’s of 
0.85 at baseline, 0.88 at three months, 0.87 at six months, 0.86 at nine months, and 0.84 at one 
year. Information on depressive symptoms reported by subjects were followed over the course of 
12 months for the current study, as this was the length of time the parent study protocol followed 
the subjects; information was not collected beyond the 12-month timeframe.  
Pharmacologic treatment. Pharmacologic treatment was defined as the use of an 
antidepressant and was the second psychological factor that was addressed in this study. The 
medication lists at three data collection points were reviewed and a variable was created for each 
subject, sorted into either taking (1) or not taking (0) antidepressants. Antidepressants from the 
following classes were included: Selective Serotonin Reuptake Inhibitors (SSRIs), tricyclic 
antidepressants (TCAs), Selective Serotonin-Norepineephrine Reuptake Inhibitors (SNRIs), 5-
HT2 Antagonists, Monoamine Oxidase Inhibitors (MAOIs), and other/combination (bupropion, 













All participants were in either the control or intervention 
group 
1= treatment 
2= control  
Depressive 
Symptoms 
Depression score measured by the short Center for 







Taking antidepressant [for example, Selective Serotonin 
Reuptake Inhibitors (SSRIs), tricyclic antidepressants 
(TCAs), Selective Serotonin-Norepineephrine Reuptake 
Inhibitors (SNRIs), 5-HT2 Antagonists, Monoamine 
Oxidase Inhibitors (MAOIs), etc.] 
1=Yes 0= No 
Length of HF 
diagnosis 
Length of time patient has had HF diagnosis (in days) Continuous 
 





Charlson Comorbidity Index Higher score = 
more 
comorbidity 
Gender Gender 1=male 
2=female  
Age Age of participant calculated as date of T1 survey minus 
year of birth 
Continuous 
 
Race Race/ethnicity as reported by subjects 1= Black or 
African 
American 
0= Others  
Income Sufficiency Monthly Income 1=can’t make 
ends need  
2=have enough 





money left over  
Live Alone Live alone 1=live alone  
2=live with 





Social Support Scale Two item scale; 1st item measures having someone to talk 
to; 2nd item measures having someone to help 
Range =1-5; 




Cardiovascular Health Markers 
The cardiovascular health markers were obtained through medical record data retrieval 
after the patient consented to be included as a study subject and signed a release of their medical 
record data. The variables included: (a) length of HF diagnosis, (b) ejection fraction (EF), and (c) 
Charlson Comorbidity Index.  
Length of heart failure diagnosis.  This variable was retrieved from the medical record 
and was recorded as number of days since the date of diagnosis with HF.  
Ejection Fraction. EF is one of most commonly used measurements of systolic function. 
The EF is the fraction of the end-diastolic ventricular volume ejected (Butterworth et al., 2013). 
Normal EF is 0.67 ± 0.08 (Butterworth et al., 2013). EF can be measured during cardiac 
catheterization, radionucleotide studies, or transthoracic or tranesophageal echocardiography. EF 
was a continuous variable. 
Charlson Comorbidity Index. The Charlson Comorbidity Index is the most extensively 
studied comorbidity index for predicting mortality (de Groot, Beckerman, Lankhorst, & Bouter, 
2003). Comorbidity is measured because it can threaten internal validity, acting as a cofounder, 
or threaten external validity, acting as an effect modifier in studies (de Groot et al., 2003). The 
index includes 17 diseases that have been selected and weighted on the basis of the strength of 
their association with mortality. The disease states included are as follows: myocardial 
infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, 
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dementia, chronic pulmonary disease, rheumatic disease, peptic ulcer disease, mild liver 
disease, diabetes without chronic complications, diabetes with chronic complications, hemiplegia 
or paraplegia, renal disease, any malignancy, moderate or severe liver disease, metastatic solid 
tumor, and AIDS/HIV (Austin, Wong, Uzzo, Beck, & Egleston, 2015).  
Concurrent validity of the Charlson Comorbidity Index was supported in four out of six 
comparisons with other comorbidity indices; predictive validity has been confirmed; and 
correlations in anticipated directions with variables supported construct validity. Test-retest 
reliability was good and interrater reliability was moderate to good (de Groot et al., 2003). The 
final score is a sum of weights, and it has been used successfully in patients with heart disease. A 
score of zero indicated no comorbidities and the higher the score the more likely the predicted 
outcome would result in higher resource use or mortality (Charlson et al., 1987).  In the original 
study the researchers used diagnoses from any hospitalizations in the past year as well as data 
from the medical record to maximize the sensitivity of identifying comorbidities.  
Biological Realm 
The patient demographic form included three self-reported variables: (a) gender 
(measured as male = 1 or female = 2), (b) age (measured as a continuous variable), and (c) race 
(measured by categories [African American = 1, Caucasian = 2, and other = 3]) (see Table 1).   
Social Realm 
 The variables selected to represent the social realm include: (a) income sufficiency, (b) 
whether or not the subject lives alone, and (c) a Social Support Scale (see Table 1).  
 Income sufficiency. Income sufficiency was measured by a single-item question, which 
states, “Which of the following statements describes your ability to get along on your monthly 
income?” Responses to this question were as follows: 1 (I can’t make ends meet), 2 (I have just 
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enough, no more), 3 (I have enough, with a little extra sometimes), or 4 (I always have money 
left over).  
 Live alone. The question used to measure whether or not participants lived alone, was a 
fill in the blank question. The questions stated, “Counting yourself, how many people live in 
your household?” This was re-coded as either lives alone (1) or does not (0).  
 Social Support. The Social Support Scale was the mean of two single items with 
responses ranging from one to five. A higher score indicated more social support (the responses 
below are reverse coded). The first question (someone to talk to) states, “During the past 4 weeks 
if you.... felt very nervous, lonely or blue; got sick and had to stay in bed; needed help with daily 
chores; or needed help just taking care of yourself. If you needed someone to listen or to help 
you, was someone there for you?” The second question (someone to help) stated, “Was someone 
available to help you if you needed and wanted help?” Responses were as follows for both social 
support questions: 1 (Yes, as much as I wanted), 2 (Yes, quite a bit), 3 (Yes, some), 4 (Yes, a 
little) or 5 (No, not at all).  
For this study a Social Support Scale was created using responses from the two social 
support questions listed above. The decision to create the scale was made because the responses 
of the two items were highly correlated with each other, r= .80 (p< .005). In this secondary data 
analysis, the Social Support Scale, when measured at baseline, had a high level on internal 
consistency as measured by Cronbach’s alpha’s of 0.88 at baseline. 
Analytic Approach 
After obtaining the de-identified data, data analysis occurred in several phases. To verify 
accurate transfer of the data descriptive statistics were calculated and compared to those reported 
in the parents study (Doolan, 2009). The number of subjects reported by the parent study was 
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verified in the data set for this study (Doolan, 2009). Power calculations were completed to 
ensure the sample size available (n=198) provides adequate power to investigate the proposed 
research questions. Using Greens rule-of-thumb, with a Power of 0.80, Alpha = 0.05, with a 
medium effect size, and 12 predictors 127 subjects would be needed (Green, 1991).  
The data analysis was completed using SPSS 23 for Mac. Descriptive statistics were 
computed to characterize the sample and to describe study variables. Response rate were 
calculated and were reported when appropriate. Scatterplots and descriptive statistics were 
examined for outliers and distributional characteristics. Specifically, for CES-D a histogram was 
completed to check for normality of the data. A Q-Q plot was completed to check the assumption 
of normality. The presence of missing data and outliers were examined and it was determined 
that no procedures were required to replace missing data, except for in the pharmacologic 
treatment data. In the pharmacologic treatment data there was 1% missing data at baseline, 
12.6% at six months and 22.2% at 12 months. After finding no features consistent within those 
with missing data the decision to carry forward the last observation was made and utilized for the 
three pharmacologic treatment variables. Some of the subjects with missing data either withdrew 
from the study or died during the course of the study.  
Research Question 1 
 Research question one was: At baseline, what is the prevalence of depressive symptoms, 
measured by CES-D, in a sample of patients with a diagnosis of heart failure who was 
hospitalized for acute decompensation prior to enrollment in the SMAC-HF trial? Descriptive 
statistics were used to describe the level of depressive symptoms at baseline using CES-D means 
and standard deviations. 
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Research Question 2: 
 Research question two was: At baseline, is there a difference in depressive symptoms 
between the self-management care intervention group and the control group? The assumptions of 
the t-test were checked and discussed in the results chapter. Differences in the depressive 
symptoms score between the two groups were going to be compared using a t-test, however due 
to assumption of normality violation a Mann-Whitney U test was completed. 
Research Question 3 
 Research question three was: What are the patterns of depressive symptoms, measured by 
CES-D, in heart failure patients at five time periods (baseline, 3 months, 6 months, 9 months, 
and 12 months) for the intervention and control groups? Means and 95% confidence intervals 
(CI) were computed and plotted for each time point. The percent of patients depressed were 
graphed over time for the intervention and control groups. Paired t-tests were completed for each 
group assignment to measure change in depressive symptoms from baseline to 12 months. The 
change score was calculated by subtracting the CES-D score at 12 months from the CES-D score 
at baseline for each participant. Additionally, an independent sample t-test was completed to 
determine if there were differences in change scores between the intervention and control groups 
from baseline to 12 months. 
Research Question 4 
 Research question four was: What are the patterns of depressive symptoms, measured by 
CES-D, in heart failure patients at five time periods (baseline, 3 months, 6 months, 9 months, 
and 12 months) for those receiving pharmacologic treatment for depression and those who are 
not by treatment group and gender? Descriptive statistics were used to further describe the 
relationship between depressive symptoms with gender and pharmacologic treatment. The mean 
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CES-D scores were plotted over time by gender to determine the patterns of depressive 
symptoms. Paired samples t-tests were completed for each gender and by pharmacologic 
treatment to measure change in depression from baseline to 12 months. The patients in the 
sample were divided into eight groups based on treatment group, gender, and baseline 
pharmacologic treatment. The mean CES-D score were plotted over time for each of these eight 
groups. 
Research Question 5 
 Research question five was: What cardiovascular health markers (i.e., length of HF 
diagnosis, ejection fraction, and Charlson Comorbidity Index), biological factors (i.e., gender, 
age, and race), psychological factors (i.e., antidepressant use) and social factors (i.e., income 
sufficiency, living alone, and social support) were associated with depressive symptoms at 
baseline? Pairwise associations between the variable of interest and CES-D were completed. 
Appropriate statistical analysis were completed to determine if the selected variables have a 
statistically significant relationship (p< .05) with depressive symptoms, measured by the CES-D. 
Variable were entered in blocks based on the biological, psychological, and social factors to 
examine the linear weighted combination of variables that explain depressive symptoms.  
 Prior to interpreting the regression, evaluation of the assumptions of regression was 
conducted: normality, linearity, independence, non-multicollinearity and constance of variance. 
A histogram and normal probability plot were used to check for normality. To evaluate linearity 
the pairwise associations between each independent variable and the dependent variable, as well 
as the partial plots for the independent variables, were assessed. Constance of variance was 
examined by checking the scatter plots for any patterns. Possible multicollinearity was addressed 
by looking at the bivariate correlation matrix, also the tolerance and Variance Inflation Factor. 
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Durbin-Watson were used to check for independence. Case wise diagnostics was used to check 
for outliers.  
Ethical Considerations 
 The SMAC-HF trial was reviewed and approved by the Institutional Review Board of a 
Midwestern academic medical center and had annual review during the study duration. During 
the parent study, progress was reviewed and approved by a Data Safety and Monitoring Board 
(Smith et al., 2014). Only de-identified data were used for this project to protect the 





 The purpose of this study was to evaluate the prevalence and patterns of depressive 
symptoms in adults with HF. Chapter four presents the demographic characteristics of 
participants in the study as well as results of the five research questions included in the 
secondary data analysis. All findings are summarized at the end of the chapter. 
Results 
Demographic Characteristics 
 Table 2 presents the patient baseline characteristics between groups that include means, 
standard deviation, and percentages. The age of patients participating in the study ranged from 
24 to greater than 90 years old, with a mean of 62.3 years. The mean ejection fraction was 
30.31% and ranged from 7% to 72%. The number of days patients had been diagnosed with HF 
ranged from four to 14,146, with a mean of 2,258 days. In regards to income, 19.7% (n= 39) of 
patients reported they can’t make ends meet; 33.8% (n= 67) have enough and no more; 31.3% 
(n= 62) have enough with little extra sometimes; and 14.1% (n= 28) always have money left 
over. There were complete CES-D data for all subjects (n= 198) at baseline. Due to subject 
attrition over the course of the 12 months of the data collection, missing data were as follows: (a) 
three months, 8.1% (n= 16); b) six months, 11.1% (n=22); (b) nine months, 19.2% (n= 38); and 






 Table 2. 
  









Age, M (SD) 62.3 (13.2) 62.6 (14.1) 62.1 (12.5) 0.78 
Male Gender, n (%) 122 (61.6) 52 (56.5) 70 (66.0) 0.17 
African American, n (%) 87 (44) 35 (38.0) 52 (49.1) 0.12 
Caucasian, n (%) 105 (53) 52 (56.5) 53 (50.0) 0.36 
Live Alone, n (%) 60 (30.3) 22 (23.9) 38 (35.8) 0.06 
Married, n (%) 83 (41.9) 42 (45.7) 41 (38.7) 0.32 
Has Children under 18, n (%) 27 (13.6) 12 (13.0) 15 (14.2) 0.84 
Currently employed for pay, n (%) 32 (16.2) 16 (17.4) 16 (15.1) 0.66 
Ejection Fraction (%), M (SD) 30.31 (16.1) 30.64 (15.6) 30.0 (16.6) 0.79 










Antidepressant Use, n (%) 42 (21.2) 17 (18.5) 25 (23.6) 0.40 
 
Research Question 1 
 At baseline, what is the prevalence of depressive symptoms, measured by CES-D, in a 
sample of patients with a diagnosis of heart failure who was hospitalized for acute 
decompensation prior to enrollment in the SMAC-HF trial? 
 Descriptive statistics (e.g., means, standard deviations) were calculated to describe the 
prevalence of depressive symptoms at baseline in the SMAC-HF trial. The baseline mean CESD 
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score for the whole sample was 8.94 (SD= 6.55); scores ranged from 0-28 (see Table 3). The 
histogram depicts the distribution of scores (Figure 2). The findings suggest that most patients 
did not have clinically significant depressive symptoms. A score of greater than or equal to 10 
has been proposed for diagnosing depression for the CES-D 10 item (Andresen et al., 1994; 
Jaarsma et al., 2010). Using the cut off score of greater than or equal to 10, at baseline 83 
participants or 41.9% of the sample were clinically depressed.  
 
Table 3.  































Research Question 2 
 At baseline, is there a difference in depressive symptoms between the self- management 
care intervention group and the control group?  
 The mean CES-D score at baseline for the control group was 8.95 (SD= 7.00), ranging 
from 0-28. The mean CES-D score at baseline for the intervention group was 8.92 (SD= 6.04) 
ranging from 0-24 (see Table 3). The assumptions for the independent t-test were checked. No 
significant outliers were noted in CES-D by group assignment, as assessed by inspection of a 
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boxplot. However, the variable was not normally distributed, as evidenced by positive 
skewness on histograms and a control skewness z-score of 3.17. Due to baseline CES-D 
violating the assumption of normality it was decided to test the difference in depression scores 
between groups using the Mann-Whitney U test.  
 The assumptions of the Mann Whitney U test were checked. The final assumption of the 
Mann-Whitney U test was met by visually inspecting the shapes of the population pyramid and 
noting the distributions are similar. The median CES-D scores at baseline were not significantly 
different (U= 5,043, z=.42, p=.68) between the intervention group (median= 8) and control group 
(median=7).  
Research Question 3 
 What are the patterns of depressive symptoms, measured by CES-D, in heart failure 
patients at five time periods (baseline, 3 months, 6 months, 9 months, and 12 months) for the 
intervention and control groups? 
 The mean CES-D scores were plotted over time by group assignment to determine the 
patterns of depressive symptoms. The graph of the mean CES-D scores over time (see Figure 3) 






Figure 3. Mean CES-D Scores over Time by Group Assignment 
 
 
 Since the mean CES-D score is below the cut-off for depression (CES-D score of ≥10), it 
is important to look at the percentages of patients depressed over time in the study. Figure 4 
depicts the percent of HF patients with depression (CES-D score of ≥10) and shows that it 






Figure 4. Percent of Patients Depressed by Group Assignment  
 
 
 To quantify further the patterns of depressive symptoms by group assignments paired t-
tests were completed for each group assignment to measure change in depressive symptoms from 
baseline to 12 months. The assumptions for the paired-sample t-test were checked. One 
significant outlier was assessed by inspection of a boxplot. Further investigation revealed the one 
outlier case was female, in the control group, and not taking pharmacologic treatment for 
depression the entire study. This outlier case had a decrease in CES-D scores from 28 at baseline 
to a score of three at 12 months. The decision was made to retain this case, as the scores for this 
subject were consistent across time periods (13, 15, and 13 at 3, 6 and 9 months, respectively). 
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The difference scores from baseline CES-D to 12 month CES-D were normally distributed, as 
assessed by visual inspection of a Q-Q plot.  
 Both group assignments noted a statistically significant (t(73)= 3.90, p< .001) mean 
decrease in depressive symptoms over time; the control group with a mean decrease of 3.40 
(SD= 5.99), t(89)= 5.38, p< .001, and the intervention group with a mean decrease of 2.80 (SD= 
6.17). An independent sample t-test was completed to determine if there was a difference in 
change scores between the intervention and control groups from baseline to 12 months. There 
was no statistically significant difference (t(154.14)= -0.63, p= .53) in mean CES-D changes scores 
between the intervention (M= 2.80, SD= 6.17) and control (M= 3.40, SD= 5.99).  
Research Question 4 
 What are the patterns of depressive symptoms, measured by CES-D, in heart failure 
patients at five time periods (baseline, 3 months, 6 months, 9 months, and 12 months) for those 
receiving pharmacologic treatment for depression and those who are not by treatment group and 
gender? 
 Descriptive statistics were used to further describe the depressive symptoms differences 
based on gender and pharmacologic treatment. At baseline, females had more depressive 
symptoms than males did. The mean CES-D score at baseline was 10.08 (SD= 7.33) for females 
and 8.23 (SD= 5.94) for males. There was a statistically significant difference (t(122.76)=-1.95, p= 
.05) in mean CES-D scores between males and females at baseline. At baseline 46.1% of females 
were depressed, while only 39.3% of males had a CES-D score of greater than or equal to 10, 
which is the cut-off score for depression. At baseline, 31.6% (n= 24) of females and 14.8% (n= 
18) of males were on pharmacologic therapy for depression. The number of patients on 
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pharmacologic treatment increased for both control and intervention groups over the course of 
the study (see Table 4).  
 
Table 4.  
Percent of Patients on Pharmacologic Treatment for Depression by Group Assignment 










 The mean CES-D scores were plotted over time by gender to determine the patterns of 
depressive symptoms. Figure 5 shows the mean CES-D scores over time for male and female 
participants. The graph reveals that both genders had reduction in depressive symptoms over the 
course of the study. Paired samples t-test did demonstrate that both genders noted a statistically 
significant mean decrease in depressive symptoms over 12 months; males had a mean decrease 
of 2.53 (SD= 5.82), t(99)= 4.35, p< .001, and females had a mean decrease of 4.06 (SD= 6.36), 








 Despite group assignment, those on pharmacologic treatment for depression had higher 
CES-D scores at baseline than those who were not. Both those taking and those not taking 
pharmacologic treatment for depression at baseline had decreased mean CES-D scores 
throughout the study regardless of group assignment (see Table 5). Paired t-test results revealed 
both those taking and those not taking pharmacologic treatment at baseline noted a statistically 
significant mean decrease in depressive symptoms from baseline to 12 months; those on 
pharmacologic treatment had a mean decrease of 5.00 (SD= 6.20), t(35)= 5.84, p< .001, and those 
not on pharmacologic treatment had a mean decrease of 2.60 (SD= 5.97), t(126)= 4.91, p< .001. 
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Table 5.  















Control No  8.04 7.15 5.52 5.01 4.94 
Yes  11.92 10.35 8.75 10.43 7.27 
Intervention No  8.26 6.18 6.08 5.51 5.49 
Yes  12.00 7.65 8.88 4.93 6.64 
 
 The patients in the sample were divided into eight groups based on treatment group 
(intervention/control), gender (male/female), and baseline pharmacologic treatment (yes/no). The 
mean CES-D score were plotted over time for each of these eight groups. In order to ease 
comparison, two separate graphs for males and females (see Figure 6 and Figure 7) were created. 
The group with the highest baseline depression level was the control female group taking 
pharmacologic treatment. All groups experienced decreases in depressive symptoms over the 
course of the study. The males not receiving pharmacologic treatment at baseline in the control 
and intervention groups appeared to have the smallest decrease in depressive symptoms over the 
























Research Question 5 
 What cardiovascular health markers (i.e., length of HF diagnosis, ejection fraction, and 
Charlson Comorbidity Index), biological factors (i.e., gender, age, and race), psychological 
factors (i.e., antidepressant use) and social factors (i.e., income sufficiency, living alone, and 
social support) were associated with depressive symptoms at baseline? 
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 Multiple regression analysis was conducted to examine which predictors influence 
depressive symptoms in HF patients. Assumptions of regression were checked: (a) independence 
of residuals, as assessed by a Durbin-Watson statistic of 1.93, was met, (b) assessment of linear 
relationships by scatter plot of the studentized residuals and unstandardized predicted values 
showed a linear relationship; (c) partial regression plots with the continuous variables showed 
linear relationships; and (d) the partial regression plot used to check for homoscedasticity 
showed that the residuals were mostly equal for all values of the predicted dependent variable.  
 Multicollinearity was assessed by reviewing the correlation table (see Table 6). All 
Tolerance values were greater than 0.1 and all VIF values were less than 10.0. The histogram 
and P-P plot both revealed the normality assumption was not violated. The assumptions of 
linearity, independence of errors, homoscedasticity, and normality of residuals were met. 
 Table 6 depicts the Pearson product-moment correlation coefficients among the 
independent variables and with the dependent variable (CES-D). There were negative small to 
moderate correlations between baseline CES-D scores and age (r= -.22), income sufficiency (r= -
34), and the social support scale (r= -.45). There was a positive correlation between baseline 





Table 6.  
Correlation among All Study Variables (n= 191). 
 
 CESD LOHF EF CCI Sex Age AA PT IS LA SSS 
CESD -           
LOHF .07 -          
EF .02 -.07 -         
CCI .09 .23** .11 -        
Sex -.15* .17** -.21* .03 -       
Age -.22** .15* .07 .27** .08 -      
AA .13* -.13* -.11 -.14* -.14* -.34** -     
PT .25** -.01 .11 .13* -.18** -.02 -.11 -    
IS -.34** .07 .13* .07 .26** .51** -.33** -.03 -   
LA .12* -.06 .02 .04 -.02 -.04 .06 .09 -.06 -  
SSS -.47** .01 .06 .07 .08 .21** -.17* -.07 .31** -.25** - 
 Key: CESD = CES-D Score, LOHF= Length of HF Diagnosis in Days, CCI = Charlson 
Comorbidity Index, Sex= Male, AA= African American, PT= Pharmacologic Treatment for 
Depression, IS= Income Sufficiency, LA=Lives Alone, and SSS= Social Support Scale.  
*p< .05; ** p< .01 
  
A multiple regression analysis was conducted to explain the variance in depressive 
symptoms using the following variables: cardiovascular health markers (i.e., length of HF 
diagnosis, ejection fraction, and Charlson Comorbidity Index), biological factors (i.e., gender, 
age, and race), psychological factors (i.e., antidepressant use) and social factors (i.e., income 
sufficiency, living alone, and social support). Regression results indicate that the overall model 
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significantly predicted depressive symptoms (F(10, 180) = 9.18, p< .0005, R- squared = 0.34, 
adjusted R-Squared= 0.30. This model accounts for 30.0% of the variance in depressive 
symptoms in patients with HF. A summary of regression coefficients is presented in Table 7 and 
indicates pharmacologic treatment, income sufficiency, and the social support scale were the 
only variables that added statistical significance (p<.05) to the explained variance. The Charlson 
Comorbidity Index was approaching the significance cut-off, and it was categorized into high 
and low levels of comorbidity, but follow-up analysis with recoded variables was still not 
statistically significant. Age also had a correlation (r= -.22) with depressive symptoms; however, 
it was not significant in the model testing. This could be due to moderate correlation of age with 
income sufficiency (r= .51), indicating that because of their shared variance, income sufficiency 














Table 7.  
Regression Coefficients for Variables explaining the Variance in CES-D 
Variable r b-weight Std.Error Beta p 
Days with HF .07 .00 .00 .08 .20 
EF .02 .02 .03 .05 .49 
CCI .09 .43 .26 .11 .09 
Male -.15 -.48 .89 -.04 .59 
Age -.22 -.04 .04 -.08 .27 
African American .13 .41 .88 .03 .65 
PT .25 3.12 1.00 .20 .00 
Income Sufficiency -34 -1.15 .52 -.17 .03 
Live Alone .12 -.12 .88 -.01 .90 
SSS .47 -2.14 .36 -.39 .00 
Key: HF= Heart Failure, EF = Ejection Fraction, CCI= Charlson Comorbidity Index, 
PT= Pharmacologic Treatment, SSS= Social Support Scale 
 
 For parsimony, the linear regression was conducted including only the variables that were 
statistically significantly (p <. 05) in explaining the variance of CES-D. The variables included in 
the second regression analysis were: pharmacologic treatment, income sufficiency, and the 
Social Support Scale. The final model, which accounts for 30% of variance in depressive 
symptoms in patients with HF can be viewed in Table 8. The regression coefficients from the 
final model analysis (see Table 9) showed that the following variables were significant (p< .05) 
in explaining the variance in CES-D at baseline: pharmacologic treatment, income sufficiency, 
and the social support scale.  
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Table 8.  
Final Model Summary 
Model R R Square 
Adjusted R 
Square 



















Table 9.  
Final Model Regression Coefficients 
Variable b weight Std. Error Beta p-value 
     
Pharmacologic Treatment 
 
3.30 .95 .21 .00 
Income Sufficiency 
 
-1.51 .43 -.22 .00 
Social Support Scale -2.10 .35 -.38 .00 
  
 
Summary of Findings 
 Depressive symptoms were present in the sample of HF patients from this study. The 
baseline mean CES-D score for the whole sample was 8.94 (SD= 6.55) and 83 participants or 
41.9% of the sample were clinically depressed (CES-D Score ≥10). The median CES-D scores at 
baseline were not statistically significantly different between the intervention group and control 
group. The intervention and control groups both had a decrease in the percent of patients with 
depression and reported depressive symptoms over time. There was not a statistically significant 
difference in mean CES-D changes scores between the intervention and control groups.  
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 At baseline, females had more depressive symptoms than males. At baseline, 31.6% of 
females and 14.8% of males were on pharmacologic therapy for depression. The number of 
patients on pharmacologic treatment increased for both control and intervention groups over the 
course of the study. Both genders had a reduction in depressive symptoms over the course of the 
study. Both those taking and those not taking pharmacologic treatment for depression at baseline 
had decreased mean CES-D scores throughout the study regardless of group assignment or 
gender. The patients in the sample were divided into eight groups based on treatment group, 
gender, and baseline pharmacologic treatment. The group with the highest baseline depression 
level was the control female group on pharmacologic treatment. All groups experienced 
decreases in depressive symptoms over the course of the study. The males not receiving 
pharmacologic treatment at baseline in the control and intervention groups appeared to have the 
smallest decrease in depressive symptoms over the course of the study. Pharmacologic treatment, 
income sufficiency, and the Social Support Scale in the final model accounted for 30% of 





 This descriptive, correlational study evaluated the prevalence and patterns of depressive 
symptoms in adults with HF. Cardiovascular health markers (i.e., length of HF diagnosis, 
ejection fraction, and Charlson Comorbidity Index), biological factors (i.e., gender, age, and 
race), psychological factors (i.e., antidepressant use) and social factors (i.e., income sufficiency, 
living alone, and social support) were investigated in relation to depressive symptoms as 
measured by the CES-D. The variables above were selected on the basis of literature review and 
The Biopsychosocial Holistic Model of Cardiovascular Health. This final chapter includes a 
summary of findings, implications of this research, theoretical relevance, strengths and 
limitations, recommendations for future research, and concludes the research findings.  
Research Findings 
 Using the Biopsychosocial Holistic Model of Cardiovascular Health (BHMCH) as the 
guiding framework, the study was designed to accomplish multiple aims: (a) to determine the 
prevalence of depressive symptoms in a sample of HF patients; (b) to determine if there are 
patterns of depressive symptoms in HF patients; (c) to investigate if the patterns of depressive 
symptoms differ in subjects receiving pharmacologic treatment or by gender; and (d) to 
determine the cardiovascular health markers and the biological, psychological, and social factors 
that were associated with depressive symptoms. The purpose of this study was achieved through 
analysis of a secondary data set generated from a randomized trial evaluating the effects of 
multidisciplinary group clinic appointments on the time to first HF re-hospitalization or death. 
Findings for each of the research questions that were addressed will be explored below.  
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Prevalence of Depressive Symptoms 
The purpose of Question one was to determine the prevalence of depressive symptoms in 
a sample of HF patients. The baseline mean CES-D score for the entire sample was 8.94, which 
is lower than the standard cut score of less than 10. These findings suggest that most patients in 
this study did not have clinically significant depressive symptoms at baseline. However, using 
the cut of score of greater than or equal to 10, at baseline 41.9% of the sample were clinically 
depressed. This is higher than reports of significant depression among 22% of patients with HF 
in general, with estimates of prevalence varying from 11% to 35% in the outpatient setting and 
35% to 70% in the inpatient setting (Rutledge et al., 2006). However, the prevalence rates of 
depression in HF patients have been found to be highly variable across studies; this could be 
partially due to the differences between studies that use self-report questionnaires and studies 
that use diagnostic interviews (Nair et al., 2012). The baseline percent depressed may also be 
higher than other reports, because all of the patients had recently been hospitalized. 
Any depressive symptoms in HF patients is concerning as they can negatively affect 
patient outcomes and quality of life. There is a continuum of depressive illness that ranges from 
mild depressive symptoms to a diagnosis of major depressive disorder (Dekker et al., 2009). 
Jiang and colleagues (2007) reported a “dose effect” for the severity of depression on survival. 
Even low levels of depressive symptoms, typically not considered “clinical depression”, are 
associated with increased mortality rates (Jiang, 2007).  
There was one outlier identified in this study, a female participant in the control group 
who was not taking pharmacologic treatment for depression the entire study. This outlier case 
had a decrease in CES-D scores from 28 at baseline to a score of three at 12 months. The 
decision was made to retain this case, as the scores for this subject were consistent across time 
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periods (13, 15, and 13 at 3, 6 and 9 months, respectively). Also, this participant would have 
been referred to a psychiatric clinical nurse specialist and received evaluation of her depressive 
symptoms, even though she was in the control group.  The study protocol was to refer all patients 
with CES-D scores of greater than 20.  
Differences in Depressive Symptoms by Study Groups 
 The purpose of Question two was to determine if there is a difference in depressive 
symptoms between the intervention and control group at baseline.  The levels of depressive 
symptoms were similar in the intervention and control group at baseline as there were no 
differences in median CES-D scores. Had an imbalance between the intervention and control 
group on depressive symptoms been found at baseline, it could have biased statistical testing that 
was completed. This finding also assured that the randomization was properly conducted and that 
both groups came from similar populations (Roberts & Torgerson, 1999). 
Patterns of Depressive Symptoms 
 Comparison by intervention and control groups. The purpose of Question three was to 
assess the patterns of depressive symptoms over time in the intervention and control groups. The 
intervention and control groups both had a decrease in depressive symptoms over time. Also, the 
percent of HF patients with depression (CES-D score of ≥10) decreased over time in both the 
control and intervention groups. There was not a statistically significant difference in mean CES-
D changes scores between the intervention and control groups. This did not correlate with the 
anticipated finding of this study, that the intervention group would have a decrease in depressive 
symptoms over the course of the study, while the depressive symptoms in the control group 
would remain the same.  
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Any decrease in depressive symptoms in HF patients is significant; treatment of 
depression in HF patients has the potential to improve quality of life, mortality and morbidity, 
and decrease the cost of healthcare and re-hospitalizations. One study found that patients who 
experience remission from depression have significantly lower cardiovascular events than those 
who did not experience remission (Jiang et al., 2011). Another study demonstrated that effective 
treatment of depression in HF patients reduced the medical costs of HF (Gottlieb, 2004). 
Therefore, it is an important finding to this study that depressive symptoms did decrease over the 
course of the study.  
Despite the decrease in depressive symptoms over time, the patterns of decreased 
depression were similar in both intervention and control groups. Due to this the affect of the 
intervention on depressive symptoms, if any, cannot be postulated. The review of literature 
revealed other studies also have identified the pattern of decreasing depressive scores in both the 
intervention and control groups (Fraguas et al., 2009; O'Connor et al., 2010; Powell et al., 2010; 
Sullivan et al., 2009). Fraguas et al. (2009) investigated the effectiveness of citalopram treatment 
for MDD in elderly patients with HF. In both groups, patients had statistically significant 
decreases in depressive symptoms (Fraguas et al., 2009). The authors concluded the findings 
were possibly due to weekly psychiatric follow-up, including counseling, for both groups.  
Another example, O’Connor et al. (2010) tested the hypothesis that HF patients treated 
with sertraline (Zoloft) would have lower depression scores and fewer cardiovascular events 
when compared with placebo. This randomized controlled trial found that antidepressants did not 
result in a significant improvement in depression when compared to the placebo. However, the 
intervention and placebo group both experienced a considerable reduction in depressive 
symptoms that was attributed to both groups receiving a nursing intervention. 
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Powell et al. (2010) completed a randomized clinical trial (RCT) to determine the value 
of self-management counseling plus HF education, when compared with HF education alone on 
time to HF hospitalization. Depression, measured by the Geriatric Depression Scale (GDS), was 
a secondary outcome. Major depressive symptoms decreased 20% in the self-management group 
and 22% in the education group. However, the authors did identify that the education component 
given to both groups contributed to active treatment, which was more than anticipated. 
 Sullivan et al. (2009) in the Support, Education, and Research in Chronic Heart Failure 
(SEARCH) study demonstrated that a mindfulness-based, psycho-educational intervention 
successfully reduced anxiety and depression at six months, but the effect was attenuated at one 
year (Sullivan et al., 2009). This was a prospective cohort study of 208 adults diagnosed with HF 
and EF less than forty percent designed to assess the impact of a mindfulness-based, psycho-
educational intervention on clinical outcomes, depression, and quality of life. Scores improved in 
treated patients when compared with control subjects from baseline to three months and from 
baseline to six months. However, both groups had improved scores thereafter so the treatment 
impact was attenuated.  
 Similar to this study, other large depression studies have found a pattern of decreased 
depressive symptoms in both intervention and control (or placebo) groups over time. As with 
other studies discussed previously, it is possible that the education component of this study (a 
short HF DVD series given to standardize the education information to both control and 
intervention groups) was an active treatment. Another possibility is the social aspect of data 
collection—i.e., phone calls for collecting questionnaire data and for recording health service 
use—became an active treatment. Even though the phone calls took minimal time, the interaction 
could have provided some support that decreased depressive symptoms. This pattern could be 
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associated with the fact that all patients in the study had recently been hospitalized. It is 
possible that participants in both the intervention and control groups were experiencing reactive 
depression; this is further discussed under the limitations section (p. 76). Further studies to 
validate the patterns found in this study are needed. 
 Comparison by pharmacologic treatment and gender. The purpose of Question four 
was to examine the patterns of depressive symptoms over time by pharmacologic treatment 
group, by control group or intervention group, and by gender. At baseline, females in this study 
had more depressive symptoms than males did. At baseline 46.1% of females were depressed, 
while only 39.3% of males had a CES-D score of greater than or equal to 10, which is the cut-off 
for depression. This is consistent with the trends in the general population as well as other 
studies, one of which found that women with HF had significantly worse depression scores than 
men (Gottlieb, 2004). Another study determined that females were more likely to have moderate 
or severe depressive symptoms when compared to males (Kao et al., 2014).  
 At baseline, 31.6% of females and 14.8% of males were on pharmacologic therapy for 
depression. Of other studies that reported the use of pharmacologic treatment for depression in 
HF patients (Gary et al., 2010; Jimenez et al., 2012), only one (Gary & Lee, 2007) provided data 
by gender (i.e., study subjects were limited to female patients only). The level of antidepressant 
use in this study might be slightly lower at 21.2% than reported in other HF studies. The studies 
found the following percent of patients with HF were taking medications to treat depression at 
baseline, prior to intervention, 33% (Jimenez et al., 2012), 47% in females (Gary & Lee, 2007), 
and 29% (Gary et al., 2010).  
 The number of patients on pharmacologic treatment increased for both control and 
intervention groups over the course of the study. No other studies addressing depressive 
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symptoms in HF patients reviewed noted an increase in pharmacologic treatment over the 
course of the study, but it is unknown whether this was measured. This finding could be due to 
the protocol in this study to refer all patients with severe depression (CES-D score of 20 or 
greater) for treatment with a Psychiatric Clinical Nurse Specialist. However, other than that 
previously discussed (pg. 44), the data regarding the referrals was not included in analysis during 
this secondary data analysis. Also, patients were given a summary at each group clinic 
appointment including their depression scores that could have led to discussions between 
primary care providers or cardiologists and their patients regarding depression and treatment.  
 Both genders had reduction in depressive symptoms over the course of the study. No 
other studies were found that described differences in gender response to interventions to treat 
depressive symptoms in HF data. Even with lower levels of depressive symptoms at baseline, the 
males also had decreased depressive symptoms. Despite group assignment, those on 
pharmacologic treatment for depression had higher CES-D scores at baseline than those who 
were not. This also was found in another research study that showed that despite treatment 64% 
of patients on antidepressants had at least mild to moderate depressive symptoms compared to 
34% who were not on pharmacologic treatment (Jimenez et al., 2012).  
 Both those taking and those not taking pharmacologic treatment for depression at 
baseline had decreased mean CES-D scores throughout the study regardless of group assignment 
or gender. This finding is supported by somewhat mixed evidence regarding the benefit of 
pharmacologic treatment in HF patients with depression. Researchers (Woltz et al., 2012) who 
conducted a systemic review addressing the effects of interventions on depression in HF patients, 
reported that despite some evidence for different pharmacologic and complementary medicine 
strategies, the review did not support the development of guidelines for the treatment of 
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depression in HF patients due to lack of sufficient evidence. There was no indication in this 
study that those on pharmacologic treatment for depressive symptoms had differing patterns of 
depressive symptoms over the course of the study when compared to those not taking 
pharmacologic treatment; both groups had decreasing depression over the course of the study. 
The only clear difference is that those on pharmacologic treatment did have higher levels of 
depression at baseline.  
 No other studies that were found in review of literature described patterns of depressive 
symptoms in different categories similar to what was done in this study. Analysis of the eight 
groups based on treatment group, gender, and baseline pharmacologic treatment revealed some 
patterns. All groups experienced decreases in depressive symptoms over the course of the study. 
The group with the highest baseline level of depressive symptoms was the female control group 
on pharmacologic treatment. The males not receiving pharmacologic treatment at baseline in the 
control and intervention groups appeared to have the smallest decrease in depressive symptoms 
over the course of the study. This finding is not surprising, based on discussion earlier that 
females and those on pharmacologic treatment have the highest levels of depressive symptoms. 
The intervention clinics were finished at approximately eight weeks after baseline data collection 
and then there was a booster session held 6 months after randomization (Smith et al., 2014). The 
graphs reveal that despite pharmacologic treatment, gender or group assignment depressive 
symptoms decreased in all groups from baseline to 3 months (after the weekly sessions were 
completed).  
 While the trends mentioned above are interesting, the clinical relevance is difficult to 
determine unless studies could be completed showing that differences in levels of depressive 
symptoms led to worse outcomes (i.e. HF rehospitalization, death, decreased quality of life, or 
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non-compliance with medication regimen). This study does reveal the pattern that those on 
pharmacologic therapy have the most variation in their depressive symptoms over the course of 
the year that data was collected.  
Depressive Symptom Determinants 
 The purpose of Question five was to determine what cardiovascular health markers (i.e., 
length of HF diagnosis, ejection fraction, and Charlson Comorbidity Index), biological factors 
(i.e., gender, age, and race), psychological factors (i.e., antidepressant use) and social factors 
(i.e., income sufficiency, living alone, and social support) were associated with depressive 
symptoms in HF patients. Regression results indicated that the overall model, with all the 
variables mentioned above, significantly accounted for about 30% of the variance in depressive 
symptoms in patients with HF. Pharmacologic treatment, income sufficiency, and the social 
support scale were the significant variables that accounted for the variance.  
 Pharmacologic treatment for depression did significantly account for variance in 
depressive symptoms in this study. As discussed in the previous section, another research study 
found that despite treatment 64% of patients on antidepressants had at least mild to moderate 
depressive symptoms compared to 34% who were not on pharmacologic treatment (Jimenez et 
al., 2012). Healthcare providers need to be aware that just because a patient is on pharmacologic 
treatment for depression, this does not mean that their depressive symptoms are low or 
controlled.  
 The relationship between income sufficiency and depressive symptoms found in this 
study is supported by findings from one other study. The study found financial burden from 
medical care was a predictor of the development of depressive symptoms in HF patients 
(Havranek, 2004). This study found that those with lower income sufficiency also had increased 
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depressive symptoms. Since income sufficiency helps describe the variance in depressive 
symptoms, health care workers need to be aware of HF patient’s ability to afford care.   
 The association between low social support and increased depressive symptoms in HF 
patients is well documented in the literature, and further supported by the findings in this study. 
One study found that depressive symptoms and poor social support had a synergistic, negative 
effect on event-free survival in HF patients (Chung et al., 2011). Another recent study 
(Friedmann et al., 2014) demonstrated that social support predicts changes in depression over 
time; patients in this study with low social support at baseline had increased depression over two 
years.  
 Health care workers with a good patient relationship should be mindful of a patient’s 
level of social support, asking if the patient has someone there to help them or to listen to them. 
They also must be aware of health care system and community resources that can be provided to 
HF patients who have low social support insufficient income and exhibiting depressive 
symptoms. Although review of literature revealed mixed results with community-based exercise 
programs or cardiac rehab for reducing depressive symptoms (Gary et al., 2010; Karapolat et al., 
2009; Koukouvou et al., 2004; Kulcu, Kurtais, Tur, Gulec, & Seckin, 2007; van den Berg-
Emons, Balk, Bussmann, & Stam, 2004), this could be considered with appropriate follow-up for 
patients with HF to provide a healthy, social outing.  
Although not significant in the model testing, an increase in depressive symptoms was 
associated with younger age, i.e., younger patients exhibited more depressive symptoms in this 
HF sample.  Similar finding from another study revealed that the patients with higher levels of 
depressive symptoms tended to be younger than non-depressed patients (Connerney & Shapiro, 
2011; Gottlieb, 2004). Though all patients with HF should be screened for depressive symptoms, 
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careful attention should be provided to younger patients who may find that it is more difficult 
accept the physical and emotional limitations caused by HF (Gottlieb, 2004). The Charlson 
Comorbidity Index was not significant in the model. No studies were found in literature review 
specifically discussing the relationship between comorbidity and depression in HF patients. 
Theoretical Relevance 
 The theoretical framework guiding this study was the Biopsychosocial Holistic Model of 
Cardiovascular Health (see Figure 1, p. 5. This model states that biological, psychological, and 
social realms interact within each person and are integrated into cardiovascular health (Thomas, 
2003). Findings in this secondary analysis partially supported the use of variables representing 
the realms of the Biopsychosocial Holistic Models (i.e., psychological, social, and biologic) in 
explaining the variance in depressive symptoms for the HF population. Specifically, this study 
supports the relationship between insufficient social support and income (i.e., social realm) and 
increased depressive symptoms, as well as pharmacologic treatment (psychologic realm) with 
decreased depressive symptoms. Variables representing the cardiovascular health markers (i.e., 
Charlson Comorbidity Index) and the biologic realms (age) were not significant in the model. 
The model provides the basis the assessment of depressive symptoms and treatment if necessary 
in patients with HF (Thomas et al., 2008). In addition to screening for depressive symptoms, it is 
important to include an evaluation of sufficient social support and income for all patients with 
HF. If deficiencies are noted appropriate referrals to community resources and social services 
need to be provided.  
Summary of Findings 
 This study adds to the body of literature about concomitant depression and HF. Study 
results supported use of variables that represented some aspects of the Biopsychosocial Holistic 
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Model of Cardiovascular Health. The body of knowledge supporting the devastating effects 
that depressive symptoms can have in HF patients is large and growing. At this time, there was a 
lack of studies focusing on patterns of depressive symptoms in HF patients and limited well-
designed studies assessing treatment options.  
 Key findings of this study are discussed below. Depressive symptoms were present in this 
sample of HF patients. The mean CES-D score (8.94) at baseline for the entire sample was below 
the cutoff score of ten. However, 41.9% of the sample was clinically depressed (CES-D Score 
≥10). There were no differences between the intervention group and control group on their 
median CES-D scores at baseline or on the mean CES-D changes scores between time periods. 
The intervention and control groups both had a decrease in depressive symptoms and percent of 
patients with depression over time.  
 At baseline, females had more depressive symptoms than males did, and more females 
were using pharmacologic therapy for depression. The number of patients on pharmacologic 
treatment increased for both control and intervention groups over the course of the study. Both 
genders had reduction in depressive symptoms over the course of the study. Both those taking 
and those not taking pharmacologic treatment for depression at baseline had decreased mean 
CES-D scores throughout the study regardless of group assignment or gender.  
 The final regression model included pharmacologic treatment, income sufficiency, and 
the Social Support Scale and explained 30% of variance in depressive symptoms in patients with 
HF. All of these variables in the model were significant. In addition to screening for depressive 
symptoms, it is important to include an evaluation of sufficient social support and income for all 
patients with HF. If deficiencies are noted appropriate referrals to community resources and 
social services need to be provided. 
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Implications 
  Based on the review of literature and the prevalence of depressive symptoms noted in 
this study, all patients with HF should be screened for depressive symptoms. It is important for 
health care workers to be aware of a patient’s income sufficiency and social support, as these 
may be closely associated with depressive symptoms. Also, just because a patient with HF is on 
pharmacologic treatment for depressive symptoms, it should not be assumed that their depressive 
symptoms are under good control.  
 Nurses play an important role in the health care of patients with HF. Both inpatient nurses 
and advanced practice nurses spend a significant amount of time directly caring for the patient 
and building a trusting relationship in a stressful time of decompensation during the 
hospitalization. Equally important are those nursing professionals in the outpatient setting who 
develop a long-term relationship with patients and see them through health and decompensation. 
Inpatient and outpatient nurses play a crucial role in identifying patients who are experiencing 
depressive symptoms and patients who are at risk for depression. The development of strong 
nurse and patient relationships, supported by a holistic care model, puts nursing professionals in 
the position to actively identify depressive symptoms, lack of social support, and insufficient 
income and provide patient-centered treatment to improve the patient’s quality of life and cardiac 
outcomes.  
 Until further specific guidelines for screening for depression in HF patients are provided, 
healthcare providers can consider the guidelines for patients with coronary heart disease. The 
American Heart Association (AHA) recommends screening for depressive symptoms in patients 
with coronary heart disease using the Patient Health Questionnaire (PHQ) two-item scale 
(Lichtman et al., 2009). The use of the PHQ-2 also is recommended in an editorial discussing the 
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treatment of depressive symptoms in HF patients by cardiologist in the Journal of the 
American College of Cardiology (Connerney & Shapiro, 2011). The PHQ-2 states, “Over the 
past 2 weeks, how often have you been bothered by any of the following problems?” with 
responses of a) little interest or pleasure in doing things or (b) feeling down, depressed, or 
hopeless (Lichtman et al., 2009). Patients who answered, “yes” to either one or both of the 
questions should be further screened with the PHQ nine-item scale.  
The guidelines also include an algorithm for care that puts patients into four arms based 
on screening results. The first arm is no changes in patients with negative PHQ-2, that represents 
no depressive symptoms. The second arm is support, education, and follow-up within one month 
for patients with positive PHQ-2 and PHQ-9 score less than ten, that represents minimal 
symptoms of short duration. The third arm is referral for more comprehensive evaluation by a 
professional qualified in the diagnosis and management of depression to determine appropriate 
therapy and provide careful monitoring of patient is indicated for (a) patients in previous group 
with worsening or persistent symptoms, (b) patients with mild to moderate depressive symptoms 
(PHQ-9 score 10-19), (c) patients with major depression (PHQ-9 score greater than 20), and (d) 
those who are safe but have had suicidal thoughts. The final arm is emergency department 
referral for all those who are suicidal and at risk for harm (Lichtman et al., 2009). The PHQ-9 is 
a clinically validated and reliable depression screening instrument that has been successfully 
used in the HF patient population (Bowden et al., 2011). A study of HF patients found that a 
positive PHQ-2 screen has been associated with subsequent mortality, providing increased 
evidence for use of this simple scale (Rollman et al., 2012).  
 More awareness regarding the prevalence, as well as the mortality and morbidity 
associated with concomitant HF and depression is needed. Upon diagnosis with HF, as with 
 77 
other chronic disease, it is important to assess a patient’s social support system and provide 
education regarding the importance of maintaining social support in reducing depressive 
symptoms. It also is important that undergraduate and masters nursing programs include 
information on screening, diagnosing, and treating depressive symptoms.  
Strengths and Limitations 
 This study provided information about patterns of depressive symptoms in HF patients, 
promoting a better understanding of these disease states. The use of an existing data set with HF 
patients and depression data provided a cost-effective way to explore depressive symptoms in 
this patient population. In this study, depressive symptoms were similar at baseline in the control 
and intervention groups. Patients who participated in this study were generally well 
representative of the HF patient population. This study represents HF patients of all age ranges 
which is important since older adults are frequently underrepresented in HF clinical trials (Mann, 
2011). 
 Despite the strengths of this study, the limitations must be considered. One limitation of 
doing secondary data analysis is that the data were not originally obtained for the purpose of 
addressing depressive symptoms or patterns of depression in HF patients (Castle, 2003). The 
parent study was limited as it was a single-center study at an academic health center, the parent 
study researchers stated that results might differ in settings where HF care is either more or less 
regimented (Smith et al., 2014). Another limitation is that there are other variables that could 
explain depressive symptoms not included in this data set.  
 This study was limited by missing data in the pharmacologic treatment variable at the 6-
month and 12-month time points. The decision to use the last observation may not have been 
representative of the use of pharmacologic treatment. Another important consideration is that 
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74% of patients invited to join the study did not participate; the main reason given was that 
they were not interested. Patients with high level of depressive symptoms may be less likely or 
unwilling to participate in a research study. Therefore the sample of this study could have 
underrepresented the depressive symptoms of the general HF population.  
 Depressive symptoms screening was conducted with the use of self-rated survey 
instruments; however, the self-rated reports are not meant to be diagnostic of depression. Few 
studies can afford the time and/or personnel needed to complete the diagnostic interview that is 
required for the determination of a diagnosis of depression. Consequently, depressive symptom 
screening scales are frequently used in the research setting (Delville & McDougall, 2008). 
Screening instruments were found to result in higher frequencies of depressive symptoms (21-
60%) when compared to diagnostic interviews (14-39%). Though the implications to the findings 
of this study are unclear, it is possible higher frequencies of depressive symptoms were noted in 
this study due to the use of a screening scale.  
 The CES-D measures depressive symptoms experienced over the past four weeks, 
making it time sensitive and more likely to detect reactive or situational depression. It is 
important to consider the possibility that depressive symptoms decreased in all participants in the 
study because they were all recruited during or within two weeks of hospitalized for an 
exacerbation of HF. Patients were randomized and depending on the rate of recruitment, it 
typically took up to three weeks after hospitalization for baseline data collection to occur (Smith 
et al., 2014). There is no way to test this hypothesis as all patients had been recently hospitalized.  
This study is a secondary data analysis of data that was collected for a different purpose 
than studying depression. The sampling of patients just discharged from the hospital with HF 
exacerbation is major limitation to this study that was not considered prior to data analysis. 
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While looking at the results of this study, planning of future studies, and caring for patients 
with HF it is important to consider that patients may be at increased risk for depressive 
symptoms after HF hospitalization. 
Recommendations for Future Research 
 The prevalence of depressive symptoms in HF patients is overwhelming and the negative 
effects of these diseases in combination are well documented. Current understanding of the 
patterns of depressive symptoms in HF patients remains incomplete.  More research is needed to 
further clarify the relationship between depressive symptoms and HF, as well as identify factors 
associated with increased depressive symptoms, in order to develop new screening and treatment 
protocols for this patient population.  
 There are further analyses that could be completed with the rich data set used for this 
secondary data analysis. Subsequent analysis could be used to further evaluate what factors were 
associated with reduction in depressive symptoms scores by using multiple regression with 
similar variables utilized in this study with the change in depressive score as the dependent 
variable.  
 The use of triangulation with qualitative data that was collected could provide rich details 
to further understand the relationship between other variables and changes in depressive 
symptoms. Analysis of the qualitative data gathered in this study could also be used to support 
the findings of this study and possibly add insight into the pattern noted with all groups having 
reduction in depressive symptoms. Qualitative data may also provide insight into whether 
reactive depression from recent hospitalization occurred in this study. Additional qualitative 
studies could examine the lived patient experience of having HF and depression, as well as 
determine the factors that the patients consider important to improving their mood.  
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Strategies to encourage screening for depressive symptoms in all patients with HF are 
needed. More research is needed to guide practice guidelines, including which depressive scales 
perform best in HF patients and best options for treatment. More pharmacologic and non-
pharmacologic studies looking at the effectiveness of existing options to treat depression in HF 
patients are needed. Also, the continued development of safe and effective pharmacologic and 
non-pharmacologic interventions to reduce depressive symptoms in HF patients is a priority.  
This study had one main finding that impacts design for future studies. Looking at the 
patterns of depressive symptoms over time revealed that depressive symptoms decreased in both 
control and interventions groups, regardless of gender or pharmacologic treatment for 
depression. The researcher postulates two possibilities for why this occurred: (a) participation in 
control group and being studied reduced depressive symptoms, and/or (b) both groups 
experienced reactive depression from recent hospitalization. Researchers designing future studies 
in this area need to be mindful of sampling procedures and which depression scale is appropriate 
based on time between data collection points. Also, special consideration needs to be given to the 
potential that the control group may benefit just from being studied.  
Conclusions 
 There has been limited research conducted on patterns of depressive symptoms in HF 
patients. This study has improved nursing knowledge by demonstrating the prevalence of 
depressive symptoms in HF patients, identifying patterns of depressive symptoms, and the 
relationship between social support, income sufficiency, and pharmacologic treatment with 
depressive symptoms. Depressive symptoms decreased with a multidisciplinary support group 
(intervention), but there also was a decrease in depressive symptoms in the control group 
 81 
possibly due to factors discussed and mental health evaluation of all significantly depressed 
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Center for Epidemiologic Studies Depression Scale (CES-D) 
 
 
(*when scoring, reverse the positive statement items # 4 [Felt happy] & #7 [Enjoyed life], 
meaning 0=3, 1=2, 2=1, 3=0) 
We are wondering about how you have felt over the past four  
weeks. Using the scale below, circle the ONE number that 
best describes how often you felt or behaved this way.  
 
















































1. Felt depressed. 0 1 2 3 
2. Felt that everything you did was an effort. 0 1 2 3 
3. Felt your sleep was restless. 0 1 2 3 
4. Felt happy.* 0 1 2 3 
5. Felt lonely. 0 1 2 3 
6. Felt that people were unfriendly. 0 1 2 3 
7. Enjoyed life.* 0 1 2 3 
8. Felt sad. 0 1 2 3 
9. Felt that people dislike you. 0 1 2 3 
10. Felt you could not get “going”. 0 1 2 3 
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Appendix B 
Patient Health Questionnaire-9 (PHQ-9) Depression Screening Scales 
Over the past 2 weeks, how often have you been bothered by any of the following problems?  
(1) Little interest or pleasure in doing things.  
(2) Feeling down, depressed, or hopeless.  
(3) Trouble falling asleep, staying asleep, or sleeping too much.  
(4) Feeling tired or having little energy.  
(5) Poor appetite or overeating.  
(6) Feeling bad about yourself, feeling that you are a failure, or feeling that you have let yourself 
or your family down. 
(7) Trouble concentrating on things such as reading the newspaper or watching television. 
(8) Moving or speaking so slowly that other people could have noticed. Or being so fidgety or 
restless that you have been moving around a lot more than usual. 
(9) Thinking that you would be better off dead or that you want to hurt yourself in some way. 
*Questions are scored: not at all= 0; several days= 1; more than half the days= 2; and nearly 
every day=3. Add together the item scores to get a total score for depression severity.  
 
 
